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A.1. Natural products 
Chemical compounds isolated from natural origins are called natural products. These 
compounds may be products of primary or secondary metabolism of diverse living 
organisms. While primary metabolites like polysaccharides, proteins, nucleic and fatty 
acids are similar in all biological systems, the chemical and taxonomic diversity of 
secondary metabolites is enormous. Additionally, the bioactivities of secondary 
metabolites are versatile in contrast to primary metabolites (Berdy, 2005). Hence, in 
most cases the term, “natural products” refers to secondary metabolites, small 
molecules produced by an organism that are not essential for the survival of the 
organism. Secondary metabolites can include products of overflow metabolism as a 
result of nutrient limitation, shunt metabolism products during stationary phase, 
defense mechanism regulator molecules, etc. (Sarker et al., 2005).  
Natural products have been used to treat human diseases since the dawn of 
medicine through the use of traditional medicines predominantly derived from plants. 
Most early therapeutic drugs such as aspirin, digitoxin, morphine, quinine, and 
pilocarpine were results of clinical, pharmacological, and chemical studies on these 
traditional medicines (Butler, 2004).  
Natural products have been reestablished as potential source of new medicines in 
scientific community in recent years. In spite of competition from other drug discovery 
methods, natural products still continue to provide novel therapeutic molecules. 40% 
of the modern drugs in use have been developed from natural products (Sarker et al., 
2005). 
A.1.1. Beginning of the era of Wonder Drugs 
Antibiotics are compounds of natural, semi-synthetic or synthetic origin which kill or 
inhibit the growth of microorganisms without significant toxicity to the human or 





animal hosts. The search for antibiotics began in the late 1800s, with the growing 
acceptance of the ‘germ theory of diseases’, a theory given by Louis Pasteur which 
linked microbes to various infectious diseases. As a result, scientists began to devote 
time to search for drugs that would kill these infection causing agents. The goal of 
such research was to find compounds that would hamper microbial growth without 
toxicity to the patient. Sir Alexander Fleming discovered the production of penicillin by 
Penicillium notatum in 1929 as a substance killing cells of Staphylococcus aureus 
(Fleming, 1929). However, it was Florey, Chain and Heatley who were later 
successful in developing a stable form of penicillin which showed significant in vivo 
activity against many Gram positive bacterial pathogens. With the conjoined efforts 
between several universities and pharmaceutical companies, the commercial 
production of first chemotherapeutic agent, penicillin from a microbe became a 
reality, thus marking the beginning of the golden age of antibiotics i.e. the “wonder 
drugs” (Demain, 2006). The advent of penicillin was followed by discovery of many 
new antibiotics from actinomycetes by Selman Waksman. Streptomycin became one 
of the most famous amongst them. The tide began to change thereafter with the 
discovery of numerous antimicrobial drugs like cephalosporins, tetracyclines, 
aminoglycosides, chloramphenicol, macrolides and many others. All these 
compounds, or derivatives thereof, are still in use as drugs today. 
A.1.2. Natural products - much more than just antibiotics 
Natural products are widely recognized in the pharmaceutical industry for their broad 
structural diversity as well as their wide range of pharmacological activities. The 
activity may be highly specific or can be unspecific or even toxic in action. Although 
natural product discovery was mainly devoted to antibiotics in the early phase, but 
between the seventies and the nineties the exploration and the wide utilization of 
natural products began e.g. as enzyme inhibitors (lovastatin, pravastatin), 
immunosuppressants (cyclosporin, sirolimus, tacrolimus and mycophenolic acid), 
antiparasitic agents (avermectins, narasin, lasalocid) bioherbicides (bialaphos), plant 
growth regulators (gibberellins), biopesticides (kasugamycin, polyoxins), 
bioinsecticides (spinosins and nikkomycin) and antitumor agents (doxorubicin, 
daunorubicin, mitomycin, bleomycin, etc.) (Demain, 2006). However, at subinhibitory 
concentrations these compounds can exhibit pleiotropic effects at different 





concentrations (Romero et al., 2011). They can act as signaling molecules that 
regulate gene expression in microbial population, or physiological functions such as 
motility, sporulation, pigmentation, quorum sensing, biofilm formation and virulence 
(Romero et al., 2011). 
A.1.3. Requisite for new natural products in future 
New and reemerging infectious diseases for which an effective therapy is still 
unavailable are a matter of concern in modern times. In addition to this, emergence 
and rise of pathogens resistant to currently used drugs present a great threat to 
disease management. Development of multidrug resistance is now gathering pace 
and contributing more substantially to the problem. This conveys an overt message 
that a continual supply of structurally novel antibiotics with multiple modes of action 
needs to be part of the antimicrobial armamentarium. A similar situation exists with 
the need to develop new cancer chemotherapeutic agents. This has given rise to an 
urgent need for identification of novel molecular scaffolds which can serve as new 
leads for effective drug development. Natural products can contribute to the process 
of drug development by their application in unmodified state in as isolated from 
nature, by providing basic chemical scaffolds that can be used to derive new 
molecules, or by signifying novel modes of pharmacological action or targets that 
allow synthesis of entirely novel analogs (Sarker et al., 2005).  
With an insight into new molecular targets, it is essential to look and screen for 
natural molecular diversity against these targets. Products from natural origin can 
play a crucial role in meeting such demand since a lot of world’s biodiversity such as 
marine environments and extreme environments still remain unexplored (Xiong et al., 
2013). Advances in technology can open access to untapped reservoir of genetic and 
metabolic diversity within the eukaryotic as well as microbial world. 
A.1.4. Microbes as a source of novel natural products 
Due to technical improvements in screening programs and chromatographic 
techniques, biological activity is observed for ~20-25% of the reported natural 
products, and 10% of these active natural products are obtained from microbes 
(Demain and Sanchez, 2009). The versatility of microbial drugs is gigantic. Microbes 
keep on producing novel metabolites as they move into the diverse ecological units. 





From the microbes that have been used so far to obtain the biologically active 
compounds, filamentous actinomycetes and fungi in particular, are the source for the 
majority of commercially exploited natural products while unicellular bacteria like 
Bacillus sp. on the other hand, more commonly, but not exclusively, produce peptide 
antibiotics like gramicidin, surfactin and subtilin.  
The fact that the secondary metabolite producing ability is not evenly distributed in 
the microbial world is indicated by the number of bioactive compounds obtained from 
fungi (Keller et al., 2005) (61%) followed by actinobacteria (Watve et al., 2001) (28%) 
both of which represent the largest groups of producers (Berdy, 2012). Mycobacteria, 
Mycoplasmatales and Spirochaetes are occasional producers unlike Bacillus 
(Fickers, 2012) and Pseudomonas species (Gross and Loper, 2009) which are most 
frequent producers amongst the prokaryotic, unicellular bacteria. Myxobacteria and 
Cyanobacteria species seem to join these distinguished organisms as recognized-
prolific species producing chemically diverse compounds (Weissmann and Müller, 
2010; Singh et al., 2011) However, the bias observed in production of bioactive 
compounds can also be attributed to the amount of work done on each of these 
groups of microorganisms over the years.  
A.2. Paenibacillus spp. as a source of natural products 
Paenibacillus is a group of endospore forming, aerobic or facultative anaerobic, rod 
shaped bacteria which belonged to the genus Bacillus until 1993 when Ash et al. 
reassigned some of the bacilli to a new genus Paenibacillus using a battery of 
phenotypic characters and a highly specific gene probe based on 16S rRNA. At 
present a total of 152 species (including subspecies) belong to this genus according 
to the Leibniz Institute DSMZ (German Collection of Microorganisms and Cell 
Cultures). Diverse ecological niches like soil, rhizospheres, diseased insect larvae, 
food, animal faeces etc. have been used as a source for isolation of novel 
Paenibacillus sp. (Saha et al., 2005). 
Paenibacillus species are notable for their ability to produce secondary metabolites 
such as antibacterial and antifungal compounds, pigments, toxins, along with 
inductors of competition and symbiosis, enzyme inhibitors, pheromones and 
promoters of vegetable and animal growth (Li-jing et al., 2011). Production of such 





secondary metabolites can confer special benefits to the producing organisms such 
as biocontrol of the competitors by scavenging minerals and nutrients and inhabiting 
the colonization sites in their natural environment (Lorentz et al., 2006). Therefore, a 
number of Paenibacillus species have been studied as a source of biologically active 
novel natural compounds and for their potential application as biocontrol agents in 
the recent past. 
The type species of genus Paenibacillus, Paenibacillus polymyxa produces peptide 
antibiotics like polymyxins, polypeptins, jolipeptin, gavaserin, saltavalin and 
fusaricidins active against bacteria, actinomycetes and fungi (Raza et al., 2009).  
Polymyxins (Stansly et al., 1947) were found to be produced by Paenibacillus 
polymyxa (formerly known as Bacillus polymyxa) and selectively active against Gram 
negative bacteria by disruption of bacterial cell membrane lipopolysaccharides. 
Polymyxins B and E (colisitin) have been regularly used in clinical practice against a 
number of pathogenic bacteria (Falagas and Kasiakou, 2006). In recent years, 
polymyxins have been shown to be effective in treatment of patients infected with 
multidrug-resistant Gram negative bacteria (Falagas et al., 2008). Martin et al. 
described another cyclic peptide antibiotic belonging to polymyxins, mattacin 
(polymyxin M) produced by P. kobensis and active against a wide variety of Gram 
positive and negative bacteria including several human and plant pathogens.  





































(R=H polymyxin B1; R=CH3 polymyxin B2)
 
Fig. A1. Structure of Polymyxin B isolated from B. subtilis 
P. alvei, strain NP75 has been reported to coproduce two new peptide antibiotics, 
paenibacillin P and paenibacillin N active against Gram positive and negative 





bacteria, respectively (Anandraj et al., 2009). A soil isolate of P. tianmuensis 
produces battacin, a cationic lipopeptide antibiotic active against some critical multi 
drug-resistant Gram negative bacterial strains of Pseudomonas aeruginosa and E. 
coli (Qian et al., 2011). In 2010, paenimacrolidin, a polyunsaturated macrolactone 
showing bacteriostatic activity against methicillin-resistant Staphylococcus aureus 
was discovered from Paenibacillus sp. (Wu et al., 2011). Additionally, P. peoriae 
(Weid et al., 2003), P. brasiliensis (Fortes et al., 2008), P. koreensis (Chung et al., 
2000) and many other species have been described to demonstrate antimicrobial 
activity though their active components have not yet been isolated.  
In conclusion, a number of Paenibacillus species continue to be studied as a source 
of biologically active novel natural compounds for their potential application in 
therapeutics and as biocontrol agents against phytopathogens like Fusarium 
oxysporum f. sp. nevium, the causative agent of fusarium wilt of watermelons (Raza 
et al., 2009).  
A.2.1. Paenibacillus larvae and its secondary metabolite potential 
Paenibacillus larvae is the etiological agent of a disastrous honey bee epidemic, 
American Foulbrood (AFB). AFB is an economically significant and a very contagious 
disease which can lead to the collapse of entire bee colonies. It is a notifiable 
disease in many countries and the effective measures for control usually involve 
burning of infected colonies to prevent the spread to other healthy colonies. Efforts to 
study the complete pathogenesis of P. larvae have thrown light on many aspects of 
the infectious disease in last few decades but a comprehensive understanding of 
disease progression and virulence factors employed by the pathogen is still lacking.  
Bacillus larvae was first described as the causative agent of AFB in honey bees (Apis 
mellifera) by Whites in 1906. Another organism named Bacillus pulvifaciens was later 
accounted for causing powdery scale disease in honey bee larvae. But both these 
species along with many others were correctly classified into genus Paenibacillus in 
1993 based on comparative 16S rRNA sequence analysis (Ash et al., 1993). 
However, strains belonging to species Paenibacillus larvae were reclassified into two 
subspecies as P. larvae subsp. larvae and P. larvae subsp. pulvifaciens based on 
possible phenotypic and genotypic differentiation and distinguished pathologies 





(Heyndrickx et al., 1996). It was in 2006 that conclusive evidence based on 
polyphasic taxonomic study on strains from both the subspecies was presented that 
justified bringing the two subspecies together into a single species, Paenibacillus 
larvae. 
Four different genotypes of P. larvae (ERIC I – IV) have been described on the basis 
of repetitive-element PCR using enterobacterial repetitive intergenic consensus 
(ERIC) primers (Genersch and Otten, 2003). The four genotypes show phenotypic 
differences in metabolism as well as in colony and spore morphology. But most 
importantly, they show differences in their level of virulence on larval and colonial 
level (Genersch et al., 2005; Ashiralieva and Genersch, 2006; Rauch et al., 2009). 
Strains of the genotype ERIC I and ERIC II are the most common field isolates from 
AFB diseased colonies while genotypes ERIC III and ERIC IV are rarely isolated. 
Experimental bioassays accomplished on honey bee larvae infected with P. larvae 
spores have revealed that P. larvae ERIC I strains have LT100 of around 13 days 
while the other three genotypes ERIC II-IV have LT100 of 5-7 days (Genersch et al., 
2005). Owing to their higher virulence and the frequency with which genotype ERIC I 
and ERIC II are encountered in diseased colony samples in nature, they are mostly 
used for in depth study of the disease. 
Paenibacillus larvae infects the honey bee larvae in their first instar stage through the 
ingestion of food contaminated with spores (Yue et al., 2008). The spores germinate 
inside the midgut lumen followed by proliferation of the vegetative cells. The 
vegetative cells then breach the epithelial barrier and colonize haemocoel. The cells 
of bacteria degrade the larvae body after its death into a thick ropy mass which later 
dry to form hard scales containing a huge number of infectious bacterial spores which 
can spread to other healthy bee colonies through various means.  
Many virulence factors like toxins (Fünfhaus et al., 2013), S-layer protein (Poppinga 
et al., 2012) and proteases (Antunez et al., 2010; Antunez et al., 2011) have been 
described in the recent years for their potential involvement in pathogenesis. Four 
fragments showing homology to the various nonribosomal peptide synthetases from 
Bacillus sp. were identified in the genome of P. larvae ERIC I and ERIC II. Precisely, 
partial sequences showing homology to the mycosubtilin synthetase subunit, iturin A 
synthetase subunit and bacitracin synthetase subunit were identified during the 





comparative genome analysis (Fünfhaus et al., 2009). The products of these gene 
clusters have been suggested to be putative virulence factors of the pathogen but 
have not yet been recognized and purified. 
A.3. Myxobacteria: a promising source of natural products 
Myxobacteria were discovered by Roland Thaxter in 1892. They are a fascinating 
group of gram negative, aerobic, δ-proteobacteria with noteworthy features like social 
behavior, gliding on solid surfaces and formation of fruiting bodies under starvation. 
The cells within the fruiting bodies become metabolically dormant and 
environmentally resistant exhibiting an impressive morphological complexity. 
Myxobacteria are found in various habitats including soil, bark of trees, decomposing 
insects and lichens, decaying plant material, dung of herbivores and marine 
environments since they can utilize a diverse array of natural macromolecules as 
food sources by secretion of exo-enzymes. In addition, they can also utilize living or 
dead bacterial, fungal or yeast cells as food in their natural surroundings. They are 
known to possess one of the largest genomes amongst bacteria (9-13 Mbp) with a 
DNA of high GC content of 66-72 mol% (Reichenbach, 1999; Goldman et al., 2006).  
However, in the last three decades the myxobacteria attracted much attention as 
promising producers of compounds with both, unique structures and bioactivities 
owing to their rich secondary metabolome. Sorangium cellulosum So ce56 which has 
one of the largest bacterial genomes is known to have around 20 secondary 
metabolite gene clusters (Schneiker et al., 2007). Secondary metabolite gene 
clusters account for 9% of genome of Myxococcus xanthus which is comparatively 
higher than many species of actinomycetes (Bode and Müller, 2005). 
The biosynthetic potential of these microbes is remarkable and has an immense 
room for exploration and exploitation. They have hitherto yielded at least 100 different 
core structures and 500 different derivatives (Garcia et al., 2009a). The majority of 
the secondary metabolites produced by myxobacteria are polyketides, nonribosomal 
peptides, or their hybrids while other structural metabolite types comprise terpenoids, 
phenylpropanoids, and alkaloids (Nett and König, 2007). Distinctive modes of action 
against a broad range of both prokaryotic and eukaryotic cells can often be observed 
by compounds isolated from myxobacteria (Weissmann and Müller, 2010). 





A.3.1. Taxonomy of myxobacteria 
All known myxobacteria are included in the order Myxococcales, which is further 
divided into three suborders, Sorangiineae, Cystobacterineae and Nannocystineae 
(Reichenbach, 2005). Novel myxobacterial taxa continue to be discovered from 
strains isolated in varied locations worldwide signifying that the myxobacterial 
diversity is yet unexplored. Availability of the 16S rRNA sequences of cultured strains 
of halophilic (Iizuka et al., 2003a,b), halotolerant (Iizuka et al., 2006) and anaerobic 
(Coates et al., 2002; Sanford et al., 2002) myxobacteria suggest the wide-ranging 
physiological and ecological niches which can be inhabited by myxobacteria. Dawid 
and colleagues isolated some psychrophilic myxobacterial species from Antarctic soil 
samples with optimal growth temperatures ranging from 4°C to 9°C (Dawid et al., 
1988). 16S rDNAs of many myxobacteria is also detected during the metagenomic 
studies but these bacteria are often termed as viable but not cultivable (VBNC) 
environmental strains (Garcia et al., 2010). Such strains are not significantly 
represented and described currently due to their unfamiliar and slightly complex 
physiological and nutritional growth requirements. A combination of new 
sophisticated isolation techniques, selective culture media, and other methods may 
make culturing such bacteria possible under laboratory conditions in future.  
With the continuous discovery of new and reclassification of some known 
myxobacterial taxa, it is immensely important to revise and update the current 
phylogeny of this group. The unique morphological traits of myxobacteria are the 
primary basis for isolation and characterization of families, genera and species and to 
identify the taxonomic status of novel strains within the order Myxococcales. 
However, such characteristics are often lost or become aberrant when the strains are 
repeatedly subcultured under laboratory conditions and so, are unreliable for 
taxonomic classification (Garcia et al., 2010). Exploration and application of some 
new molecular taxonomic approaches along with the traditional ones is necessary to 
alleviate some of these problems and to clearly delineate a potential new taxon from 
its closest relatives (Shimkets and Woese, 1992). The novel tools available for 
systematics include the complete 16S rRNA gene sequencing and its comparative 
analysis by phylogenetic trees, DNA-DNA hybridization studies with related 
organisms, analyses of molecular markers and signature pattern(s), biochemical 





assays, physiological and morphological tests. All these genotypic, chemotaxonomic 
and phenotypic tools in combination with each other or all together can furnish 
substantial information for elucidating the reliable taxonomic position of a microbe 
and constitute a polyphasic approach for taxonomic studies.  
 
Fig.A2. Systematic description of myxobacteria with in order Myxococcales (orange). Three suborder (yel low) and 
seven families (green) are also indicated. Aetherob acter (blue) is a novel unpublished genus. (Garcia et al., 2009b; 
Mohr et  al., 2011; Iizuka et al., 2003; Iizuka et  al., 2013)  
Progress in polyphasic approach has become an important tool in bacterial 
systematics and should be applied more effectively for myxobacteria to classify newly 
isolated strains as well as reclassification of strains placed under invalid taxa. 
Recently, cellular fatty acid analysis has been used for chemo-taxonomic 
classification of myxobacteria and it has been proven to be a valid tool to verify the 
rDNA based phylogeny (Garcia et al., 2011). More such molecular markers or 
methods need to be determined for deciphering accurate phylogenetic relationships 
between the closely related taxa. Following a polyphasic approach will progressively 
pave the way for modern myxobacterial systematics rooted in the genetic lineages of 
the organisms.  
A.3.2. Treasure from myxobacterial metabolome 
The myxobacterial metabolome is unique both in structural diversity and biological 
activities. About 40% of the myxobacterial compounds that have been described 





represent novel chemical scaffolds while others comprise structural elements already 
known from other organisms like streptomycetes and cyanobacteria but modified by 
myxobacteria into new compounds (Reichenbach, 2001). Only in very rare events, 
structures exactly identical to compounds known from other sources were identified 
from myxobacteria suggesting the diverse chemical space of the myxobacterial 
metabolome.  
These findings have motivated more research efforts to identify lead compounds 
amongst the myxobacterial secondary metabolites for clinical application. One of the 
most celebrated compounds from myxobacteria is epothilone B which was isolated 
from Sorangium cellulosum. It was found to possess cytotoxic activity against mouse 
fibroblast cell line L929 and human T-24 bladder carcinoma cell line (Gerth et al., 
1996a). It was hence further investigated and exhibited selective activity against 
breast and colon tumor cell lines in the in vitro antitumor screening program of the 
National Cancer Institute (Höfle et al., 1996). A semi-synthetic analogue of epothilone 
B, ixabepilone (Ixempra®) was the first natural product of myxobacterial origin 
approved for clinical use in 2007 for treatment of breast cancer (Hunt, 2009). 
Disorazols, (Elnakady et al., 2004), tubulysins (Sasse et al., 2000), rhizopodin 
(Jansen et al., 2008), chivosazols (Diestel et al., 2009) and chondramides (Sasse et 
al., 1998) all act on cytoskeletal elements and need to be evaluated for development 
to potential anticancer drugs (Kaur et al., 2006; Elnakady et al., 2004; Khalil et al., 
2006). In addition to affecting the cytoskeletal elements, myxobacterial compounds 
can also act on a number of other target sites inside the eukaryotic cells. Argyrins 
(Nickeleit et al., 2008) and gephyronic acid (Sasse et al., 1994), for example, both 
isolated from the myxobacterium Archangium gephyra exhibit cytotoxic activities by 
inhibition of proteasome activity and inhibition of protein synthesis, respectively.  
Approximately 54% of the bioactive myxobacterial metabolites exhibit antifungal 
activity (Gerth et al., 2003) following varied mechanism of actions. The main target of 
such compounds like stigmatellin (Thierbach et al., 1984), myxothiazol (Thierbach 
and Reichenbach, 1981), haliangicin (Fudou et al., 2001) and myxalamid (Gerth et 
al., 1983) is the mitochondrial respiratory chain. Soraphen, a polyketide metabolite 
produced by Sorangium cellulosum came into limelight upon revelation of its unique 
mode of action which targeted the fungal Acetyl-CoA-carboxylase (Gerth et al., 





1994). Its mechanism of action became a model for novel test systems, e.g. showing 
small-molecule inhibitors of human ACCs have potential in the treatment of metabolic 
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Fig.A3. Natural compounds from myxobacteria with cy totoxic, antifungal and antibacterial activity (Wei ssman and 
Müller, 2010) 
Out of the huge repertoire of myxobacterial metabolites, around 29% show activities 
against various bacteria (Gerth et al., 2003) and these antibacterial compounds use 
varied mode of actions. DNA-dependent RNA polymerase is the key enzyme of 





transcription in all living organisms, and hence, also a crucial target for antibacterial 
therapy. Myxobacterial compounds like corallopyronin (Irschik et al., 1985), 
myxopyronin (Irschik et al., 1983a), ripostatins (Irschik et al., 1995) and sorangicins 
(Irschik et al., 1987) can serve as lead structures for development to effective drugs 
specifically targeting the eubacterial RNA polymerase. Etnangien (Irschik et al., 
2007a) has the ability to inhibit bacterial RNA polymerase as well as DNA 
polymerase, making it an interesting lead molecule for further investigation.  
Thuggacins (Irschik et al., 2007b) show activity against selective Gram positive 
bacteria by inhibition of the cellular electron-transport chain (Steinmetz et al., 2007). 
Protein synthesis is inhibited by angiolam (Kunze et al., 1985), althiomycin (Kunze et 
al., 1982) and myxovalargin (Irschik et al., 1983b). Myxovirescins (Gerth et al., 1982) 
specifically inhibit incorporation of N-acetyl-glucosamine during murein synthesis 
leading to disruption of the cell wall synthesis. 
In the continuing efforts to exploit the myxobacterial secondary metabolism, many 
new compounds have been identified and described recently including roimatacenes 
produced by Cystobacter ferrugineus (Zander et al., 2011), hyaladione isolated from 
Hyalangium minutum (Okanya et al., 2012) and icumazoles (Barbier et al., 2012) 
which were described as a new class of antifungals from Sorangium cellulosum. 
Another highly potent compound, carolactone (Jansen et al., 2010) which inhibits 
biofilm formation by Streptococcus mutans was isolated from Sorangium cellulosum 
(Müller and Wink, 2013).  
A.3.3. Quest for novel myxobacteria and their metabolites 
The strain collection at the Helmholtz Centre for Infection Research has continued to 
expand over the last few decades and currently comprises more than 8000 isolates 
of myxobacteria and other gliding bacteria. Our ongoing screening of this huge strain 
collection for bioactive molecules, which can serve as potential drug candidates or 
leads in future, has revealed the remarkable ability of myxobacteria to synthesize 
novel natural products with unique structures. A bulk of the compounds isolated from 
myxobacteria come from selected genera, such as Sorangium, Myxococcus and 
Chondromyces sp., reflecting the non-uniform potential to produce secondary 
metabolite within the myxobacterial species (Garcia et al., 2009). However, this 





conclusion is based upon the production under laboratory conditions and may vary in 
their natural environments. Another striking feature is the commonly observed 
similarity in the secondary metabolite profiles of strains belonging to the same 
suborder (Gerth et al., 2007). This aspect can be exploited for chemotaxonomy of 
myxobacteria using selected secondary metabolites as biomarkers. 
Additionally, production of a family of closely related metabolites with varied biological 
activity rather than a single natural product with unique structure is often observed for 
myxobacteria (Gerth et al., 2007). For example, Sorangium cellulosum can produce 
at least 30 different variants of epothilone upon fermentation (Gerth et al., 2007). In 
contrast, a single myxobacterial strain can also produce a huge repertoire of 
structurally unrelated secondary metabolites based on their genetic potential.  
Sampling from biologically complex or extreme environments increases the likelihood 
of isolation of novel myxobacterial taxa (Dawid, 2000). Forest soil samples which are 
usually enriched with decaying plant matter and animal dung can serve as an 
excellent source for isolation of novel strains (Garcia et al., 2009). Such extremely 
intricate environments seem to be ideal for fostering new myxobacteria and their 
interaction and competition for limited common resources act as important factors for 
the development of bioactive secondary metabolites. Recently, 58 halotolerant strains 
were isolated using conventional isolation methods from saline-alkaline soil samples 
collected in Xinjiang, China (Zhang et al., 2013). Some of these strains could grow at 
salt concentration as high as 2% while others formed fruiting bodies at 1% salt 
concentration displaying their osmotolerance, which is quite unusual in terrestrial 
myxobacteria.  
Additionally, refined isolation and baiting techniques, selective culture media, and 
other methods could possibly lead to discovery of novel taxa (Garcia et al., 2010). 
For example, Anaeromyxobacter dehalogenans was isolated on the basis of its ability 
to grow using acetate as an electron donor and 2-chlorophenol as an electron 
acceptor (Sanford et al., 2002). It was described as first myxobacteria taxon with the 
ability to grow under facultative anaerobic conditions. Isolation methods involving 
different prey strains as bait for myxobacteria and imitating natural predatory 
environment are also often helpful in myxobacterial isolation (Li et al., 2013).  





Identification, isolation and screening of new myxobacteria over the last three 
decades have led to the discovery of many new compounds. This implies that the 
probability of finding uncharacterized metabolites increases with isolation and 
screening of novel families, genera or species of myxobacteria. Isolation of 
aetheramides, potent HIV inhibitory molecules isolated from the novel myxobacterial 
genus, Aetherobacter (not validly published) clearly exemplifies the potential of new 
taxa in production of new molecules (Plaza et al., 2012). Aetheramides were found to 
be active against fungi and human colon tumor cell line (HCT-116) but most 
importantly against the virus, HIV-1. Indiacens were also isolated and purified as 
compounds with antibiotic activity against certain bacteria and filamentous fungi from 
another novel myxobacterial genus, Sandaracinus amylolyticus, (Steinmetz et al., 
2012). 
Bioassay-based screening and fractionation, and HPLC-coupled mass spectrometry 
of the crude extracts from selected strains form a part of conventional methods in 
drug discovery. Apart from these commonly used screening and de-replication 
processes for identification of novel myxobacterial products, new approaches need to 
be implemented in order to discover yet unidentified metabolites. Co-cultivation with 
other soil bacteria and mimicking the natural environment during cultivation could be 
employed as new strategies for screening for potential new bioactive compounds 
from already known taxa as well as novel taxa. 
A.4. Process of drug development from microbial natural 
products 
In a classic microbe-based natural product program, microbiologists isolate pure 
cultures of microorganism from environmental samples collected from the biosphere.  
Environmental samples can vary from the traditional soil samples to leaf litter, tree 
barks, animal dung and beetle carcasses but each kind of environmental sample has 
its own characteristic microbial spectrum (Borris, 1996).  
Extracts from small scale fermentations of the isolated pure cultures are then 
screened on a panel of preliminary assays. Cultures that are found to be active in 
one or more assays are again grown under similar conditions to check the 
reproducibility of the original activity before the culture extract is subjected to some 





form of dereplication.  
Dereplication, the process of determining whether the active compound is novel is a 
vital part of any natural product program. A finely designed and executed 
dereplication process helps to avoid wasting resources and allows focusing on 
unique molecules and activities. Isolation and identification of the active constituent 
follows the dereplication process for the positive extracts. Optimization of media and 
growth conditions is also often crucial to obtain higher yields of compounds. Isolation 
of the active compounds is performed by various subsequent chemical processes 
guided at each step by bioassay data. The molecular structure of the compound is 
determined using various spectroscopic and chemical techniques like NMR 
spectroscopy and X-Ray crystallography. Isolation of the pure compound at larger 
scale is then carried out after optimization of all the biological as well as chemical 
procedures.  
After the isolation and identification of the compound, it must be evaluated against 
the entire spectrum of specific assays to identify its molecular targets and potential 
toxicity or side effects to normal eukaryotic cells. Eventually, the potential lead 
compound has to undergo a rigorous safety assessment program which involves 
tests on several species of animal and with high doses of compound. Any significant 
toxicity in any species of test animals even at very high doses of compound can lead 
to termination of active interest in a compound by a pharmaceutical company. In 
case the compound passes through safety assessment, it has to undergo clinical 
trials before it reaches the market.    
A.5. Challenges and benefits of microbial drug discovery program 
High-throughput screening from all natural sources presents a number of challenges. 
The problem of reliable access and supply is of utmost concern. Even slight 
variations in growth conditions of the microbes can sometimes cause difficulties with 
production and initial detection of active compounds as well as subsequent repetition 
of assays or purification. Loss of production of the anticipated compound is also 
possible upon repeated sub-culturing under laboratory conditions. Even if supply is 
consistent, the initial raw extract usually consists of a complex mixture of various 
compounds including media components which need to be separated from the 





desired compound using successive separation techniques. The raw extract might 
also contain only very small quantities of a bioactive substance and often as a 
mixture with structurally related molecules or its own derivatives and the initial 
concentration might be too low to be effectively detected by high-throughput 
screening. Additionally, the primary screening assays may be disguised by poor 
solubility of the compound or by fluorescent or colored false positives. Furthermore, 
the activity observed from a raw extract during the primary screening could be due to 
the synergistic activity of two constituents that may then diminish or disappear upon 
separation. The key compound can also be unstable making isolation a challenging 
task. Finally, extensive study is often required for complete structural elucidation of 
the compound to be absolutely sure that the molecule is novel. 
Microorganisms also implicate a number of advantages in a natural products 
discovery program compared to other sources of natural products. Firstly, the 
diversity of the microbes taxonomically as well as biochemically is enormous. The 
accessibility of a wide range of microbes makes a high screening throughput both 
practical and lucrative. One of the major advantages of working with microorganisms 
is the ability to screen vast numbers of cultures on a small scale and production of 
large quantities of microbial products by fermentation. It is unlikely that continuous 
supply becomes a hurdle in the development of a microbial product. The innumerable 
antibiotics derived from microbial natural products currently in use imply the real 
potential of microbes as source of lead drugs in future.        
A.6. Aim of this thesis 
The main goals embedded in this thesis include identification of novel microbial 
natural products and myxobacterial taxa. In this framework, one of the first objectives 
was to screen two Paenibacillus larvae and 50 myxobacterial strains using a 
comprehensive reactivation-process with up-to-date methods. After the screening 
was accomplished, the focus was set on P. larvae ERIC II (DSM 25430) and 
Nannocystis pusilla, Ari7 for purification of uncharacterized secondary metabolites. 
Large scale fermentations were carried out for P. larvae ERIC II (DSM 25430) and N. 
pusilla, Ari7 followed by bioassay guided separation for purification of compounds. 
Structure elucidation of the pure compounds was done using NMR spectroscopy and 
mass spectrometry. Furthermore, amino acid composition, sequence and 





stereochemistry were analyzed for the compounds obtained from P. larvae. Finally, 
the biological activities of the pure compounds which were isolated in sufficient 
amounts were tested against a panel of bacteria, fungi and yeasts along with various 
cell lines. 
Additionally, 16S rRNA gene sequences of the same set of 50 myxobacterial strains 
were analyzed. Strain MCy1366T (Ar1733) was found to be branching out from rest of 
the known strains in the family Myxococcaceae and was selected for further 
investigation. MCy1366T along with the 9 type strains from family Myxococcaceae 
was also studied and compared for antibiotic resistance, fatty acid composition using 
GC-MS and cytoplasmic proteome using MALDI-TOF analysis. In addition, strain 
MCy1366T was subjected to many physiological tests to ascertain its position as a 
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Paenibacillus larvae has been extensively studied in past few decades as an appalling 
honey bee pathogen. In the present work, we screened P. larvae genotype ERIC I and 
II crude methanol extracts for antimicrobial activity based on the detection of 4 
secondary metabolite gene clusters showing homology to various known antibiotic 
clusters during complete genome sequencing project. Paenilarvins, iturinic lipopeptides 
exhibiting strong antifungal activity were identified and purified guided by bioactivity 
assays from cultures of P. larvae ERIC II. The molecular structures were determined 
using 1D, 2D NMR spectroscopy and mass spectrometry. Nonribosomally synthesized 
peptides can yield a plethora of advantages to the producing organisms from survival 
benefits to regulation of metabolism and virulence, apart from some being 
pharmaceutically significant, e.g. in the form of antibiotics. Paenilarvins represent the 
first secondary metabolites isolated and characterized from P. larvae. These 
lipopeptides may play a role in P. larvae survival and pathogenesis but further studies 
are needed to investigate their function in detail.  
B.2. Introduction 
American foulbrood (AFB), one of the most catastrophic honey bee (Apis mellifera) 
epidemics, is a notifiable disease in many countries and strict laws are enforced for its 
regulation. Burning of infected or diseased colonies is considered the most effective 
control measure against AFB in most countries bringing huge losses. Despite being a 
deleterious and economically significant disease for honey bees, the complete 
molecular pathogenesis of AFB remains obscure.  
Paenibacillus larvae, a Gram positive, rod shaped and spore forming bacterium which 
only infects the larvae in first instar stage through its spores, is the etiological agent of 
AFB. Genotyping of P. larvae isolates on the basis of repetitive-element PCR using 
enterobacterial repetitive intergenic consensus (ERIC) primers identified four genotypes 
of P. larvae (P. larvae ERIC I – IV) (Genersch et al., 2006) which vary in varied aspects 





but most importantly, in their level of virulence (Genersch, 2010; Genersch et al., 2005; 
Rauch et al., 2009). Strains of the genotypes ERIC I and ERIC II are the most common 
field isolates and account for most of the AFB outbreaks worldwide, making them most 
significant genotypes for study. 
Fluorescence in situ hybridization (FISH) using P. larvae-specific, 16S rRNA targeted 
oligonucleotide probes was used to study the interaction between the host and the 
pathogen (genotype ERIC I and II) in detail (Yue et al., 2008). This study gave a deep 
insight of the disease progression starting from the ingestion of spores of P. larvae by 
the honey bee larvae through contaminated food to the formation of hard scales from 
dead larval remains. These hard scales are the source for millions of bacterial spores, 
which can further be transmitted by use of contaminated equipment or by adult honey 
bees feeding on contaminated honey within a colony as well as between colonies.  
A number of potential virulence factors have been described to be instrumental in P. 
larvae pathogenesis in recent years. The P. larvae secretome was studied in detail and 
established as a source of some of these factors (Antunez et al., 2010). Enolase, 
produced by P. larvae was identified as a highly toxic and immunogenic protein to Apis 
mellifera larvae (Antunez et al., 2011a). P. larvae was also detected to produce 
metalloprotease in vivo during bee larvae infection (Antunez et al., 2011b). Both 
aforementioned enzymes have been reported to be possibly involved in larval 
degradation during and after infection. Poppinga et al. (2012) recently established the 
functional S-layer protein, SpIA of P. larvae ERIC II as an important virulence factor. 
The latest report on the subject has affirmed that P. larvae ERIC I strains produce AB 
binary toxins, Plx1 and Plx2 as virulence factors (Fünfhaus et al., 2013). 
Lately in an attempt to identify all the putative virulence genes in P. larvae,  suppression 
subtractive hybridization (SSH) was applied for comparative genomics of P. larvae 
genotypes (Fünfhaus et al., 2009) and several fragments showing homology to 
nonribosomal peptide synthetases (NRPSs) and polyketide synthetases (PKSs) 
subunits belonging to the iturin family lipopeptides, bacitracin and bacillomycin were 





identified in different genotypes. Open reading frames showing close homology to 
NRPSs of the antibiotic plipastatin and surfactin were also observed in another study on 
P. larvae genome using a combination of bioinformatics and proteomics (Chan et al., 
2011). NRPS and PKS are giant multifunctional enzyme systems with numerous 
domains bundled together into functional modules responsible for nonribosomal 
assembly of secondary metabolites. The end products of such complex multistep 
biosynthetic process are nonribosomal peptides (NRP) or polyketides (PK) or their 
hybrids with broad structural diversity and biological activities like enzyme inhibitors, 
immunosuppressants, antiparasitic agents, bioherbicides, plant growth regulators, 
biopesticides, bioinsecticides, antitumor agents as well as in microbial survival and 
pathogenesis (Demain, 2006; Romero et al., 2011). 
Our interest in natural products from bacterial and fungal sources and confirmation of 
the presence of NRPSs and NRPS/PKS hybrid clusters in P. larvae DSM 25719 (ERIC 
I) and DSM 25430 (ERIC II) genome (Djukic et al., 2014), allured us to examine P. 
larvae for the production of novel secondary metabolites which could be of significance 
to the pathogen and possibly as pharmaceuticals or agrochemicals. In this study we 
identified and isolated a group of related lipopeptides, paenilarvins from P. larvae DSM 
25430 (ERIC II), elucidated the molecular structure of the major products and 
determined their biological activity. All the isolated paenilarvins belong to the iturin 
family of lipopeptides and are closely related to mojavensin A, an iturinic lipopeptide 
produced by marine-derived bacterium Bacillus mojavensis B0621A (Ma et al., 2012).  
B.3. Results and Discussion  
B.3.1. Bioactivity screening of P. larvae DSM 25719  and DSM 25430 
The potential of P. larvae for the production of bioactive secondary metabolites was 
confirmed following complete genome sequencing of P. larvae DSM 25719 (ERIC I) and 
DSM 25430 (ERIC II) which has been recently reported by Djukic et al. Four different 
NRPS or NRPS/PKS hybrid clusters were identified during this study based on genome 
analysis and comparison with variations in domain organization and size of clusters 





between the two genotypes.The two strains were grown in the presence of an absorber 
resin (Amberlite XAD 16) and the crude methanol extracts were tested for their 
antimicrobial activity against a panel of microorganisms including gram positive and 
gram negative bacteria, yeast and filamentous fungi in 96 well plate diffusion assay.  
Crude extracts of DSM 25719 (ERIC I) and DSM 25430 (ERIC II) showed activity 
against Nocardia flava, Staphylococcus aureus, Chromobacterium violaceum and 
Mucor hiemalis.  However, while the antibacterial activity was not reproducible, the 
antifungal activity against M. hiemalis was persistent in extracts from various batches of 
shake flasks.  Also, crude extracts from DSM 25430 strain were much more bioactive in 
comparison to DSM 25719 extracts against M. hiemalis with MIC value of 2.1µg/ml for 
the former strain. These results prompted us to follow the observed antifungal activity 
and investigate the production of these antifungal compounds by P. larvae DSM 25430 
(ERIC II). 
Paenibacillus spp. have been described as an accomplished source of biologically 
active secondary metabolites in a number of previous studies (Li-jing et al., 2011; Raza 
et al., 2009; Stansly et al., 1947; Anandraj et al., 2009; Qian et al., 2011; Wu et al., 
2011). Therefore, bioassay guided HPLC fractionation and MS spectrometry was 
implemented to P. larvae DSM 25430 extract to detect the antifungal compounds. This 
displayed the presence of a group of closely related peptides ranging in their molecular 
masses from 1069 Da to 1112.7 Da. The mass range of the identified compounds was 
closely related to iturin family compounds like mycosubtilin, mojavensin produced by 
Bacillus spp. (Peypoux et al., 1986; Ma et al., 2012) but a detailed structural analysis 
was essential for complete characterization. 
B.3.2. Structural analysis of paenilarvins  
P. larvae DSM 25430 strain (ERIC II) was fermented in 5L scale with XAD-16 amberlite 
adsorber resin which was collected and eluted with methanol to give a crude extract at 
the end of fermentation. Successive chromatography of the crude methanol extract on 
silica gel and reverse phase column guided by antifungal activity against M. hiemalis, 





yielded 7 compounds belonging to the paenilarvin group. The most active compounds, 
paenilarvins A and B were used for further structure elucidation and biological assays. 
The complete molecular structures of paenilarvins A and B were determined by mass 
and nuclear magnetic resonance (NMR) (1D and 2D) spectral analysis. 
Paenilarvin A (1) was obtained by RP-HPLC as colorless amorphous powder. The 
positive HRESIMS spectra presented a molecular ion cluster at m/z 1112.6108 [M+H]+ 
consistent with the molecular formula C52H82N13O14 (calcd. 1112.6099), which was 
supported by the 13C NMR spectrum. The intense IR absorptions between 1600 and 
1700 cm-1 and between 3100 and 3400 cm-1 showed the presence of amide C=O and 
NH groups, respectively. The weak UV band at 277 nm and 223 nm was in good 
agreement with a peptide containing aromatic amino acids. Among all 52 carbon in 
signals the 13C NMR spectrum of 1 displayed 13 amide carbonyl signals between 172.7 
and 177.9 ppm and 8 methine carbons in the range between 48.5 and 63.2 ppm as it 
could be expected for a small peptide. Correspondingly, the complex 1H NMR spectrum 
of 1 furnished 17 H/D exchangeable protons between 6.75 ppm and 8.75 ppm and at 
least 8 methine protons in the range 4.05 to 5.0 ppm. A detailed analysis of COSY, 
TOCSY, HSQC and HMBC data for paenilarvin A (1) (Fig.B1) in CD3OH solution 
revealed the presence of four asparagine, one tyrosine, one glutamine, and one proline 
residues (Table B1). Furthermore, the methylene group (δC 44.2, δH 2.49, 2.41) and the 
methine (δC 48.5, δH 4.15) adjacent to the doublet of 23NH (δH 7.49, 9.5 Hz) were 
recognized as parts of a long ß-amino-acid. The methyl doublet (δC 19.7, δH 0.86) and a 
methyl triplet (δC 11.8,δH 0.87) signals and the combination of the remaining methine (δC 
35.7, δH 1.29) and methylene signals (δC 30.6, , δH 1.32, 1.13) by 
1H,1H COSY and 
1H,13C HMBC correlations completed the structure of this part as 3-amino-14-methyl-
hexadecanoic acid (ß-Aa). The sequence of the amino acid residues in 1 was 
established by analysis of HMBC and ROESY correlations showing connections of the 
α-methine protons of amino acid residues to carbonyl carbons of the neighboring 
residues as comprised in Fig.B2 and Table B1.  
 






Fig. B1. Structures of paenilarvins A (1), B (2), a nd C (3). 
B.3.3. Mass spectrometric analysis   
The sequence of the amino acid residues was analyzed by ESI TOF MSMS and on 
Orbitrap FTMS mass spectrometer analyzer. The full scan spectrum of (1) showed a 
single and a doubly-charged molecular ions at m/z 1112.6108 [M+H]+ and m/z 556.8098 
[M+2H]2+ (Fig.BS12) while the MS1 spectrum of Paenilarvin B (2) showed similar single 
and doubly-charged ions at m/z 1113.5963 [M+H]+ and m/z 557.3026 [M+2H]2+ 
(Fig.BS25). Equally the MS1 spectrum of (3) showed values at m/z 1084.5804 [M+H]+ 
and m/z 542.7948 [M+2H]2+ (Fig.BS39). For further investigations the MS2 spectra of 
(1) were analyzed. Based on the m/z [M+H]+ 1112.610 two fragments at m/z 707.44 and 
m/z 406.17 were observed. These two fragments are in conclusion with the partial 
amino acid sequence: Pro, Asn, Asn, ß-Aa, Asn and additionally the sequence Gln, 
Asn, Tyr, both in good agreement with the HMBC- and ROESY-NMR data. The 
compounds 1 and 3 showing the same amino acid sequence of Gln, Asn, Tyr, Asn, ß-
Aa, Asn, Asn, Pro but different ß-amino-acid side chains. MS3 spectra showed the 
immonium ion for the side chains: (NH2
+=CH-CH14H29) that could also be identified for 
compound 1 and 2 at m/z =226.167, as well as for compound 3 (NH2+=CH-C12H25) at 
m/z =198.220. 






Table B1. 1H (700 MHZ) and 13C (175 MHz) NMR data of paenilarvin A (1) in CD 3OH 
Amino 
acid 
Position δC  δH ( J in Hz) COSY HMBC ROESY 
Selected signals 
       
       
Gln 1 172.8   2, 2NH, 46  
 2 51.7 4.65 (m) 3ab, NH 3ab, 4ab 49ab 
 3a 
3b 
27.9 2.11 (m) 
2.06 (m) 
2, 3b, 4ab 











2, 5NH2  
 5 177.8   3, 4ab, 5NH  
 2NH  7.46 (d, 8.0) 2  2, 3ab 
 5NH2  7.53(s), 6.81(s)   3ab, 4ab 
       
Asn4 6 173.1   2, 2NH, 7, 8ab  
 7 52.5 4.64 (m) 7NH, 8ab  8ab  
 8a 
8b 






 9 175.0   7, 8ab, 9NH2  
 7NH  8.28 (d, 6.7) 7 11 8ab, 11 
 9NH2  7.54 (s), 6.85 (s)   8ab 
       
Tyr 10 174.3   7, 11NH, 12ab  
 11 58.4 4.28 (m) 11NH, 12ab  12ab 12ab, 14 
 12a 
12b 




11, 14 11, 12b, 14 
 13 128.6   11, 12ab,15  
 14* 131.3 7.06 (d, 8.4) 15 12ab 11, 12ab 
 15* 116.5 6.72 (d, 8.4) 14   
 16 157.4   14,15  
 11NH  8.49 (d, 8.0) 11  12ab, 18  
       
Asn3 17 175.0   11, 11NH, 18, 
19 
 18 52.7 4.61 (dd, 13.5, 7) 18NH, 19ab  19ab  
 19a 
19b 




18, 20NH2 18 
18, 23, 24b 
 20 174.6   18 ,19, 20NH2  
 18NH  8.01 (d, 4.7) 18  22ab, 23 
 20NH2  7.58 (s) 6.81 (s)   19ab 
       
ß-amino- 
acid 
21 174.2   18NH  
(ß-Aa) 22a 
22b 
44.2 2.49 (m) 
2.41 (d, 14.0) 
23 
23 
23NH, 24a 23NH, 24a 
23, 24b 
 23 48.5 4.15 (m) 22ab, 23NH, 
24ab  
21, 22ab 22b, 24b, 25-33 
 24a 
24b 
36.2 1.65 (m) 
1.50 (m) 
23, 25ab  
23, 25ab  
22b 22a, 23, 23NH, 25-
33 






 25-33 27.1-31.2 1.33-1.09 (m)    
 34 35.7 1.29 (m) 34Me, 35 34Me, 36Me  
 34Me 19.7 0.86 (d, 6.2) 34 33, 35  
 35a 
35b 




34Me, 36Me  
 36Me 11.8 0.87 (t, 7.3) 35ab 34  
 23NH  7.49 (d, 9.5) 23  23, 38 
       
Asn2 37 173.6   23NH, 39ab  
 38 51.7 4.92 (m) 38NH, 39ab  39ab  
 39a 
39b 
38.8 2.97 (dd, 15.7, 
5.1) 




40NH2 40 NH2 
39a 
 40 174.9   39ab, 40NH2  
 38NH  7.73 (d, 7.5) 38  38, 39b 
 40NH2  7.44 (s), 6.85 (s)   39ab 
       
Asn1 41 172.9   38,43  
 42 52.0 4.48 (m) 42NH, 43ab  43ab  
 43a 
43b 
36.7 2.92 (m) 
2.84 (dd, 16, 4.5) 
42, 43b 
42, 43a 
42, 44NH2 42, 44NH2 
42 
 44 175.4   42, 44NH2  
 42NH  8.55 (d, 6.9) 42  46, 47 
 44NH2  7.61(s), 6.85(s)   43ab 
       
Pro 45 175.4   46, 47ab  
 46 63.3 4.23 (dd, 7.5, 7.5) 47ab 47, 48, 49ab 47a, 8b 
 47a 
47b 




46 46, 48b 
 48a 
48b 






46, 47a, 49b 47a 
 49a 
49b 
49.1 4.01 (m) 




2, 47a, 48b 2, 48b, 49b 
2, 48a, 49a 
 
 






Fig. B2. Key HMBC and ROESY correlations of paenila rvin A (1)  
The stereochemistry of paenilarvin A (1) was determined by Marfey’s method (Marfey, 
1984; Bhushan and Bruckner, 2004). After final hydrolysis the solution was compared 
with standard L- and D-amino acids and authentic amino acid derivatives by co-
injection. Thus, paenilarvin A (1) was found to contain 1 (L)-Pro, 2 (L)-Asn, 2 (D)-Asn, 1 
(L)-Gln, and 1 (D)-Tyr. The positions of the D- and L-Asn residues were assigned by 
analysis of the 2D ROESY spectrum analogously to the cyclic lipopeptides maribasins A 
and B, which similary comprise seven amino acid residues and the same type of side 
chain (Zhang et al., 2010). Accordingly, the stereochemistry was deduced by mapping 
the 2D ROESY correlations between the α-proton and the amide proton of amino acid 1 
(AS1) and between the amide proton of AS1 and the α-proton of AS2, that both have 
the same configuration.  The strong ROESY correlation from the Asn1 amide proton (δH 
8.55) with the L-Pro α-proton (δH 4.23) and the absence of a correlation with the Asn1 α-
proton (δH 4.48) indicated that the amino acid side chain is on the opposite side of the 
main plain of the molecule. Thus, Asn1 was assigned to have D configuration. The Asn2 
amide proton (δH 7.73) neither showed a correlation with the Asn1 α-proton (δH 4.48) nor 
with the Asn2 α-proton (δH 4.92), which implied L configuration for Asn2. ROESY 
correlations of the amide protons and α-protons of Asn2, ß-proton of ß-Aa and Asn3 
showed that they were on the same side, respectively. Thus, ß-Aa and Asn3 had L 





configurations (Fig.B1). Corresponding to the D configuration of Tyr derived by Marfey’s 
method, a ROESY correlation of the Tyr amide proton (δH 8.49) with the Asn3 α-proton 
(δH 4.61) was found but no correlation with the Tyr α-proton (δH 4.28). The ROESY 
correlation of the amide proton (δH 8.28) of Asn4 with the α-proton (δH 4.28) of Tyr and 
with the α-proton (δH 4.64) of Asn4 suggested D configuration for Asn4. In contrast, no 
correlation of amide proton (δH 7.46) of the L Gln with the α-proton of Asn4 was 
observed. Consequently, the structure of paenilarvin A (1) was finally established as 
cyclo L-Pro-D-Asn1-L-Asn2-L-ß-amino-14-methylhexadecanoic acid-L-Asn3-D-Tyr-D-
Asn4-L-Gln. 
B.3.4. Antimicrobial and cytotoxic activity of paen ilarvins  
Screening of pure paenilarvins, A (1) and B (2) obtained from P. larvae DSM 25430 
(ERIC II) for antimicrobial activities against a broad panel of bacteria, fungi and yeasts 
showed no activity against the group of Gram positive and negative bacteria tested. 
However, both lipopeptides showed activity against most of the fungi and yeasts but 1 
showed much better activity compared to 2 with minimum inhibitory concentration (MIC) 
as low as 2.1µg/ml against Trichosporon oleaginous, Aspergillus clavatus, Botryotinia 
fuckeliana and Hormoconis resinae (Table B2). Compound 2 was not significantly active 
against all the fungi and yeast tested with a lowest MIC value observed as 16.6µg/ml. 
When 1 and 2 were tested for their cytotoxicity against mouse fibroblast cell line L929, 1 
was again found to be much more active (LD50 4µg/ml) than 2 which showed no 
significant cytotoxic activity (LD50 >10µg/ml).  
Lipopeptides belonging to the iturin family (iturin, mycosubtilin, bacillomycin and 
bacillopeptin) have long been known to possess strong antifungal and haemolytic 
activity, but show only restricted antibacterial effects (Maget-Dana and Peypoux, 1994). 
Thus, the strong antifungal activities of iturins producing organisms make them 
promising candidates as biocontrol agents. Mojavensin A was also found to be active 
against soil borne phytopathogens like Fusarium oxysporum f. sp. cucumerinum and 
Valsa mali and weakly inhibitory to Staphylococcus aureus (Ma et al., 2012). However, 





anteiso – C15 mojavensin A is not as active against fungi as other iturins. Hence, the 
strong antifungal activity and no antibacterial activity of compounds 1 and 2 against our 
test organisms correspond to the biological activity data available for other iturins. 
Table B2. Minimum inhibitory concentration (MIC) in  µg/mL of paenilarvin A (1) and B (2) 





Saccharomyces cerevisiae (DSM 70449) 4.2 33.3 4.2[b] 
Rhodotorula glutinis (DSM 10134) 4.2 16.6 <0.52[b] 
Candida albicans (DSM 1665) 4.2 n.i. 8.3[b2] 
Wickerhamomyces anomalus (DSM 6766) 4.2 16.6 2.1[b] 
Nematospora coryli (DSM 6981) 4.2 33.3 3.3[b] 
Trichosporon oleaginous (DSM 11815) 2.1 16.6 0.52[b] 
Debaryomyces hansenii (DSM 3428) 4.2 n.i. 8.3[b] 











i Mucor hiemalis (DSM 2656) 4.2 33.3 2.1
[b] 
Aspergillus clavatus (DSM 816) 2.1 8.3 2.1[b] 
Botryotinia fuckeliana (DSM 877) 2.1 16.6 2.1[b] 
Hormoconis resinae (DSM 1203) 2.1 16.6 < 0.25[b] 










 Nocardioides simplex (DSM 20130) n.i. n.i. 16.6[a] 
Nocardia sp. (DSM 43069) n.i. n.i. <0.52[a] 
Staphylococcus aureus (DSM 346) n.i. n.i. 0.1[a] 
Micrococcus luteus (DSM 20030) n.i. n.i. 3.3[a] 














Pseudomonas aeruginosa (DSM 50071) n.i. n.i. 0.13[c] 
Chromobacterium violaceum (DSM 30191) n.i. n.i. 1.0[a] 
[a] Oxytetracyclin hydrochloride, (1mg/ml); [b] Nystatin, (1mg/ml in MeOH); [b2] Nystatin, (1mg/ml in DMSO);  [c]  Gentamycin (1mg/ml); 
Paenilarvin A and B (1mg/ml in MeOH); n.i. – no inhbition 
 
B.4. Conclusion 
P. larvae is pathogen of great economic as well as environmental concern because of 
its ability to cause one of the most serious and contagious diseases of honey bees, 
American foulbrood. We have come a far way in understanding P. larvae and its 





pathogenicity in the last century but several aspects of the biology of the pathogen still 
remain elusive. In our study, we explored the secondary metabolite potential of P. 
larvae owing to the identification of genome segments homologous to putative NRPSs 
and PKSs clusters of closely related organisms like Bacillus subtilis (Fünfhaus et al., 
2009; Chan et al., 2011). 
Out of the four NRPS or NRPS/PKS hybrid clusters identified during complete genome 
sequencing and annotation of P. larvae DSM 25719 (ERIC I) and DSM 25430 (ERIC II), 
one of the clusters was found to show significant similarity to the NRPS/PKS hybrid 
clusters encoding for iturin family synthetases present in Bacillus subtilis (Djukic et al., 
2014). Iturin family compounds have been characterized as lipopeptides with a β-amino 
fatty acid chain linked to a circular heptapeptide produced by Bacillus sp. (Maget-Dana 
and Peypoux, 1994). The first report of production of an iturin like compound by a 
Paenibacillus sp. came in 2000 from a chitinolytic bacterial strain, Paenibacillus 
koreensis YC300T, isolated from a compost sample collected from Chinju, Republic of 
Korea (Chung et al., 2000) but the complete molecular structure of the compound was 
not described.  
In the course of this study, we were able to identify a group of antifungal compounds 
within the mass range from 1069.7 Da to 1112.7 Da in our bioactivity guided assays 
with crude extracts of P. larvae DSM 25430 (ERIC II). Purification and molecular 
characterization of the compounds using mass spectrometry and NMR spectroscopy 
clarified that the compounds belong to iturin family and the complete structure 
elucidation of the purified compounds revealed two major cyclic compounds produced 
by the strain, paenilarvins A and B. Paenilarvin A has the same amino acid sequence as 
mojavensin A (Ma et al., 2012) except that the ß- Aa side chain is extended by two 
methylene units. Paenilarvin B has the same side chain as paenilarvin A but contains an 
aspartic acid instead of asparagine in position Asn2. 
Paenilarvins A and B showed no antibacterial activity but strong antifungal activity 
against rare human pathogenic species like Aspergillus clavatus and Penicillium 





capsulatum and phytopathogens like Nematospora coryli and Botryotinia fuckeliana. 
Paenilarvins also exhibited significant activity against a commercially important fuel 
contaminant fungus, Hormoconis resinae (Haggett and Morchat, 1992). Cytotoxic 
activity against mouse fibroblast cell line L929 was also observed during the study.  
Production of paenilarvins by the pathogen in vitro raises the question of their potential 
involvement and function in the pathogenicity of P. larvae. Production of secondary 
metabolites usually serves survival functions in the producing organisms in their 
ecological niche (Demain and Fang, 2000) as these compounds can generate 
competitive advantage in nature but may also be employed by a producing 
microorganism for an entirely different purpose. Considering the fact that honey bees 
are exposed to a lot of pathogens like parasitic mites, small hive beetle, microsporidian 
parasites, viruses and fungi, (Campano et al., 1999; Murray and Aronstein, 2008) it can 
be speculated that P. larvae produces paenilarvins to be dominant amongst these 
potential pathogens. Certain microbes also show entomopathogenic activity, infecting 
and killing insects by production of secondary metabolites (Kanoaka et al., 1977). 
However, these hypothesis can only be ascertained by examining the inhibitory effects 
of these compounds against prospective honey bee pathogens and honey been larvae. 
It is also known that antibiotics can exert diverse effects at subinhibitory concentrations 
and their response depends upon the concentration used, a concept called as 
hormensis (Calabrese and Baldwin, 2002; Davies et al., 2006). The analysis of effect of 
subinhibitory antibiotic concentrations have demonstrated regulation of key biological 
processes including transcription, translation, transport of exoproteins, stress response, 
quorum sensing, and biofilm formation (Romero et al., 2011). This has also been 
studied in regard to virulence and pathogenic properties of a number of bacteria 
(Aminov, 2009). In 2011, aureusimine A and aureusimine B were determined to be 
regulators of virulence factor expression for exotoxins, γ hemolysin, regulatory, redox 
associated superantigen like genes in S. aureus (Wyatt et al., 2011). Paenilarvins A and 
B could also be involved in regulation of physiological processes in P. larvae which can 
only be confirmed upon a deep investigation on molecular level.   





It is noteworthy that production of paenilarvins was only detected in P. larvae ERIC II 
(DSM 25430, DSM 16116) and none at all in ERIC I (DSM 25719, DSM 7030). This 
observation is supported by the genome sequencing and annotation data revealing the 
presence of an incomplete NRPS/PKS cluster in the DSM 25719 (ERIC I) genome. 
However, we still observed some antibacterial and antifungal activity in crude extracts of 
P. larvae DSM 25719 strains during our preliminary experiments indicating that they 
have the potential to produce some other biologically active secondary metabolites 
which still need to be discovered.  
In this study, we could purify and characterize one group of secondary metabolites 
produced by P. larvae DSM 25430 (ERIC II), which possibly plays an important role for 
the pathogen. However, their precise function in pathogenesis needs still to be 
determined. The presence of other biosynthetic clusters is obvious from the genomic 
data obtained for the pathogen suggesting that other important secondary metabolites 
remain undiscovered (Djukic et al., 2014; Fünfhaus et al., 2009). Further studies are 
needed to unravel the products of these biosynthetic clusters and to investigate their 
exact role in pathogenesis. A comprehensive understanding of P. larvae pathogenesis 
combined with molecular evidence on virulence factors can pave the way for effectively 
dealing with this devastating honey bee disease in the future. 
B.5. Experimental Section 
B.5.1. General Experimental Procedures 
Spectral and physico-chemical data were obtained with the following instruments: NMR 
spectra were recorded on a Bruker Ascend 700 TCI cryo probe spectrometer (1H 700 
MHZ, 13C 176 MHz) using CD3OH as solvent. All 2D NMR spectra were analyzed using 
ACD NMR Spectrus software. IR spectra were recorded on a Perkin-Elmer FT-IR 
spectrometer. UV spectra were measured on a Shimadzu UV/Vis-2102 spectrometer 
with methanol as solvent. Optical rotation: Perkin Elmer 241 MC spectrometer, solvent 
methanol. Mass spectra were obtained on a Bruker maXis UHRTOF using electrospray 





ionization (ESI) in positive mode, molecular formulae were calculated including the 
isotope pattern (Smart Formula algorithm) and in addition ESI TOF MSMS on Finnigan 
LTQ Orbitrap Mass spectrometer. Analytical HPLC: Gradient in 25 min. Solvent A: 5% 
acetonitrile 95% water + 5mM NH4CH3COO, pH 5.5 (40µL CH3COOH/L); Solvent B: 
95% acetonitrile 5% water + 5mM NH4CH3COO, pH 5.5 (40µL CH3COOH/L); flow: 
600µL/min.; Temperature 40°C; column: Waters Acquit y BEH C18, 50 x 2.1mm, 1.7µm 
equipped with the corresponding pre-column. 
B.5.2. Bacterial strain and growth conditions 
Four P. larvae isolates representing genotypes ERIC I (DSM 25719, DSM 7030) and 
ERIC II (DSM 25430, DSM 16116) were used for the study. The strains had been 
cryopreserved at -80°C. DSM 25430 was reactivated i n 20mL of modified MYPGP broth 
(Nordström and Fries, 1995) with beef infusion replaced by 2% meat extract and 0.2% 
vitamin solution at neutral pH. The strain was then sub-cultured to 600mL in the same 
medium in Erlenmeyer’s flasks and used as a seed culture. Scale-up fermentation 
(5.2L) of the strain was performed in 1L Erlenmeyer’s flasks each containing 350ml of 
the modified MYPGP media supplemented with 2% Amberlite XAD-16 resin and 
incubated at 30°C, 160rpm for 6 days. The XAD resin  was separated and collected from 
the culture at the end of fermentation by sieving. 
B.5.3. Extraction and isolation of active compounds  
1L of methanol was used for elution from the adsorber XAD resin packed in a glass 
column. Methanol was evaporated from the extract to give a dry crude material of 6.14g. 
This extract was separated on 120g of silica gel in an open column equilibrated with 
ethyl acetate. Elution from the silica gel was made using ethyl acetate and increasing 
percentage of methanol from 100% ethyl acetate to 100% methanol to obtain mainly 4 
fractions. The organic solvent from each fraction was evaporated.  
Fractions 3 (1.19g) which was eluted with 2L of 50/50 (v/v) ethyacetate and methanol 
from silica gel was dissolved in methanol and passed through RP cartridge [Strata™-X 
33µm, Polymeric Reversed Phase, 200mg/6 mL] and concentrated to 6mL. Processed 





sample was further purified by four runs of preparative RP-HPLC [column 250 × 
21.2mm, Phenomenex Gemini® C18, 10µm, 110Å; solvent A: acetonitrile/H2O 37/63 + 
0.1% formic acid; solvent B: acetonitrile/H2O 40/60 + 0.1% formic acid; gradient: 0% B 
for 35min and 100% B from 35 to 80min; flow rate 20mL/min; UV detection at 210nm]. 
The fractions contained pure paenilarvin A (1) 6.8mg, paenilarvin B (2) 3.9mg, and 
paenilarvin C (3) 12.8mg along with other related peptides. 
B.5.4. Assignment of absolute stereochemistry of am ino acid residues  
Marfey’s method was used for determining the stereochemistry of amino acid residues 
in paenilarvins. 1.1 mg of the lipopeptide was hydrolysed in 0.5 mL of 6 N HCL at 110°C 
overnight. Then, the sample was dried in vacuum. 50 µL Water, FDAA (Marfey’s 
reagent, 100 µL) in acetone and 1 M sodium-hydrogen carbonate (20 µL) were added to 
the hydrolyzed products and the mixture heated at 41°C for one hour. 10 µL 2M HCL 
was added later to stop the reaction and the mixture was evaporated to dryness. The 
residue was dissolved in 0.5 mL Water/ DMSO 1:1 and analyzed with reversed-phase 
chromatography [column 2.1x50 mm, Waters Acquity UPLC BEH C18, 1.7µm; gradient 
acetonitrile/water 5/95 + 0.1% formic acid to acetonitrilie/water 40/60 + 0.1% formic acid 
in 30 min; flow rate 0.6 mL/min; UV detection: DAD, MS-spectrometer AmazonTM Bruker 
ESI mode. 
B.5.5. Structural characteristics of paenilarvins 
Paenilarvin A (1) white, solid; UV (methanol) λmax (log ɛ) 223 (4.27 sh), 277 (3.35) nm; 
[α]D +15.4° ( c = 0.039, DMSO); Rt: 10.9min; v = 3383, 2927, 2855, 1668, 1541, 1517, 
1384cm-1; 1H and 13C NMR (see Table B1); HRESIMS: m/z 1112.6108 [M+H+] (calcd. 
for C52H82N13O14, 1112.6099). 
Paenilarvin B (2) white, solid; UV (methanol) λmax (log ɛ) 223 (4.23), 277 (3.35) nm; [α]D 
+6.4° ( c = 0.075, methanol); Rt: 11.1min; 
1H NMR (CD3OH + 5µL HCOOH, 700 MHz) 
selected signals: for Asp: δC 173.0ppm (C37), n.o. (C38), 37.6 (C39), 175.4ppm (C40), 
δH  4.87 (m, H38), 3 and 2.84 (m, H39a,b), 7.78 (38NH); HRESIMS: m/z 1113.5953 [M 
+ H+] (calcd. for C52H81N12O15, 1113.5939). 





Paenilarvin C (3) white, solid; UV (methanol) λmax (logɛ) 223 (4.80), 277 (3.35) nm; [α]D 
+11.8° ( c = 0.221, DMSO); Rt: 9.6min;  
1H NMR (DMSO-d6, 700MHz) selected signals: 
end of the side chain: -CH2 (δC 38.5, δH 1.24, 1.13), -CH (δC 27.4, δH 1.49, m), -(CH3)2 
(δC 22.5, δH 0.84, d, 6.7,  Hz); HRESIMS: m/z 1084.5790 [M + H+] (calcd. for 
C50H78N13O14, 1084.5785). 
B.5.6. Antimicrobial assay  
The MIC of compounds 1 and 2 was determined against the Gram-positive bacteria 
(Staphylococcus aureus, Nocardia flava, Micrococcus luteus, Nocardioides simplex and 
Paenibacillus polymyxa), Gram-negative bacteria (Chromobacterium violaceum, 
Pseudomonas aeruginosa), filamentous fungi (Mucor hiemalis, Aspergillus clavatus, 
Hormoconis resinae, Penicillium capsulatum, Botryotinia fuckeliana) and yeasts 
(Saccharomyces cerevisiae, Candida albicans, Rhodotorula glutinis, Nematospora 
coryli, Trichosporon oleaginous, Debaryomyces hansenii, Pichia membranifaciens and 
Wickerhamomyces anomalus). Bacterial test strains were cultivated in EBS medium 
(0.5% casein peptone, 0.5% protease peptone, 0.1% meat extract, 0.1% yeast extract, 
pH 7.0) and fungi in MYC medium (1.0% phytone peptone, 1.0% glucose, 50 mM 
HEPES [11.9g/L] pH 7.0) at 30 – 37°C, 160rpm for 24 -48hrs and the cell concentration 
adjusted to OD600 0.01 for bacteria and OD548 0.1 for yeasts. 10µL aliquots (conc. 
1mg/mL in MeOH) of 1, 2 and 5µl aliquots of reference drugs (oxytetracycline 
hydrochloride (Sigma), 1mg/mL in water; nystatin dihydrate (Sigma), 1mg/mL in MeOH 
or DMSO and gentamycin (Serva), 1mg/ml in water) were used. The MIC values were 
determined in 96 well microtitre plates by 1:1 serial dilution, as previously described 
(Okanya et al., 2011). The lowest concentration of the drug preventing visible growth of 
the test strains was taken as the MIC.  
B.5.7. Cytotoxicity assay  
Compounds 1 and 2 were also tested for their cytotoxic activity against mouse fibroblast 
cell line L929. The IC50 value was determined using MTT assay as previously described 
(Okanya et al., 2011). 
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Figure BS1. 1H NMR of 1 in CD 3OH,   700 MHz 































Figure BS2. 13C NMR of 1 in CD 3OH, 176 MHz 
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Figure BS3. 1H-1H COSY NMR of 1 in CD 3OH, selected area 
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Figure BS4. 1H-1H COSY NMR of 1 in CD 3OH, selected area 
 
 
Figure BS5. HSQC NMR of 1 in CD 3OH, selected area 
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Figure BS6.  HMBC NMR of 1 in CD 3OH, selected area  
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Figure BS7.  HMBC NMR of 1 in CD 3OH, selected area 
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Figure BS8.  TOCSY NMR of 1 in CD 3OH, selected area 
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Figure BS9.  TOCSY NMR of 1 in CD 3OH, selected area 
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Figure BS10.  ROESY NMR of 1 in CD 3OH,   selected area 
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Figure BS11.  ROESY NMR of 1 in CD 3OH,   selected area 
 































































Figure BS15. 13C NMR DEPT of 2 in CD 3OH +5 µL HCOOH, 176 MHz, selected area 
 































Figure BS17. 1H-1H COSY NMR of 2 in CD 3OH +5 µL HCOOH, 700 MHz, selected area 















Figure BS18. 1H-1H COSY NMR of 2 in CD 3OH +5 µL HCOOH, 700 MHz, selected area 
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Figure BS19. HSQC NMR of 2 in CD 3OH +5 µL HCOOH, 700 MHz, selected area 























Figure BS20. HMBC NMR of 2 in CD 3OH +5 µL HCOOH, 700 MHz, selected area 
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Figure BS21. HMBC NMR of 2 in CD 3OH +5 µL HCOOH, 700 MHz, selected area 






















Figure BS22. TOCSY NMR of 2 in CD 3OH +5 µL HCOOH, 700 MHz, selected area 
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Figure BS23. TOCSY NMR of 2 in CD 3OH +5 µL HCOOH, 700 MHz, selected area 





















Figure BS24. ROESY NMR of 2 in CD 3OH +5 µL HCOOH, 700 MHz, selected area 
 
 
Figure BS25. ESI HRMS of paenilarvin B (2) 
 

























Figure BS26: 1H NMR of 3 in DMSO-d 6, 700 MHz 
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Figure BS27. 13C NMR of 3 in DMSO-d 6, 176 MHz 
 



















Figure BS28. 1H-1H COSY NMR of 3 in DMSO-d 6, selected area 
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Figure BS29. 1H-1H COSY NMR of 3 in DMSO-d 6, selected area 


















Figure BS30. HSQC NMR of 3 in DMSO-d 6 +5 µL HCOOH, 700 MHz, selected area 
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Figure BS31. HMBC NMR of 3 in DMSO-d 6, 700 MHz, selected area 





















Figure BS32.  HMBC NMR of 3 in DMSO-d 6, 700 MHz, selected area 
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Figure BS33. HMBC NMR of 3 in DMSO-d 6, 700 MHz, selected area 



















Figure BS34.  HMBC NMR of 3 in DMSO-d 6, 700 MHz, selected area 
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Figure BS35.  TOCSY NMR of 3 in DMSO-d 6, 700 MHz, selected area 

















Figure BS36.  TOCSY NMR of 3 in DMSO-d 6, 700 MHz, selected area 
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Figure BS37.  ROESY NMR of 3 in DMSO-d 6, 700 MHz, selected area 

























Figure BS38.  ROESY NMR of 3 in DMSO-d 6, 700 MHz, selected area 
 
 
Figure BS39. ESI HRMS of paenilarvin C (3) 
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A novel myxobacterium MCy1366T (Ar1733) was isolated in 1981 from a soil sample 
collected from a region near Tokyo, Japan. It displayed general myxobacterial 
features like Gram negative staining, rod shaped vegetative cells, gliding on solid 
surfaces, microbial lytic activity, fruiting body-like aggregates and myxospore-like 
structures. The strain was mesophilic, aerobic and showed chemoheterotrophic 
mode of nutrition. It was resistant to many antibiotics like cephalosporin C, 
kanamycin, gentamycin, hygromycin B, polymyxin and bacitracin and the key fatty 
acids of whole cell hydrolysates were iso-C15:0, iso-C17:0, and iso-C17:0 2-OH. The 
genomic G+C content of the novel strain is 65.6 mol%. The 16S rRNA gene 
sequence showed highest similarity (97.60%) to “Stigmatella koreensis” strain KYC-
1019 (not validly described taxon, GenBank accession no. EF112185). The 
phylogenetic analysis based on 16S rRNA gene sequences and MALDI-TOF data 
revealed a novel branch in the family Myxococcaceae. DNA-DNA hybridization 
showed only 28% similarity between the novel strain and the closest species, 
Corallococcus exiguus DSM 14696T (97% 16S rRNA gene sequence similarity). A 
recent isolate from a Switzerland soil sample and designated reference strain, 
MCy10622 displayed 99.9% 16S rRNA gene similarity and showed almost the same 
characteristics with MCy1366T. Since some morphological features like fruiting body 
like aggregates were barely reproducible in the type strain, the newly isolated strain 
MCy10622 was also intensively studied. On the basis of a comprehensive taxonomic 
study, we propose a novel genus and species, Aggregicoccus edonensis gen. nov., 
sp. nov., for strain MCy1366T and MCy10622. The type strain for the genus 
Aggregicoccus is MCy1366T (=DSM 27872T =NCCB 100468T).  
C.2. Introduction 
Myxobacteria are known for their unique life cycle and the ability to produce natural 
products with unique structures and bioactivities (Weissman and Müller, 2010). They 
form a phylogenetically coherent group within the class δ-proteobacteria based on 
16S rRNA gene sequence analysis (Garcia et al., 2010). Three suborders, 7 families, 
23 genera and 55 species with valid names have been published within the order 





Myxococcales until today (Approved List of Bacterial Names). Myxobacterial 
systematics is mainly based on morphological characteristics like shape and size of 
vegetative cells and myxospores, swarming colonies and fruiting bodies. However, 
their morphological characteristics are often unstable and may vary or be lost on 
repeated subculturing under laboratory conditions (Garcia et al., 2010). 16S rRNA 
gene sequences are also quite conservative for fine discrimination between closely 
related taxa (Fox et al., 1992). Hence, a polyphasic approach should be followed in 
order to clearly delineate a potential new taxon from its closest relatives. Recently, 
fatty acid analysis with respect to different taxonomic clades within myxobacteria 
helped to establish chemotaxonomic-phylogenetic correlations (Garcia et al., 2011). 
In the future, other molecular markers and approaches also need to be identified and 
applied to establish a modern myxobacterial systematics. 
Using divergent approaches based on genotypic, phenotypic and chemotaxonomic 
analysis performed together with the reference strain MCy10622 and selected type 
strains belonging to the genera Myxococcus, Corallococcus, Pyxidicoccus, and 
Melittangium, we propose a new genus for a soil bacterium from Japan, MCy1366T. 
C.3. Results and Discussion 
Two strains described here were isolated from different geographical locations in 
different time and place. MCy1366T was isolated at the Helmholtz Centre for Infection 
Research (HZI; formerly GBF, Gesellschaft für Biotechnologische Forschung, 
Braunschweig, Germany) in 1981 from a soil sample, collected in 1980 near Tokyo, 
Japan. The reference strain MCy10622 was isolated in July 2013 at the Helmholtz 
Institute for Pharmaceutical Research Saarland (HIPS, Saarbrücken, Germany) from 
a soil sample collected from Zürich, Switzerland. Standard isolation and purification 
protocols were used for both strains (Reichenbach and Dworkin, 1992). The type and 
neotype strains used in this study are listed in Table S1 in the supplementary 
information. All strains were continuously maintained on CY/H medium supplemented 
with 1 ml l-1, 500 fold diluted vitamin solution after autoclaving (Mohr et al., 2011; 
Schlegel, 1992) and VY/2 agar. All cultures were incubated at 30°C, liquid cultures at 
160 – 200 rpm unless specified otherwise.  





Morphology of vegetative cells and myxospores was studied with phase-contrast 
microscopy (Olympus BX51). Fruiting body like aggregates (for MCy1366T), fruiting 
bodies (for MCy10622) and swarming colonies were observed under an Olympus 
SZX12 stereomicroscope and Zeiss Discovery.V20 stereomicroscope on P (Garcia et 
al., 2009), VY/2 and CY agar (Shimkets et al., 2006). All photographs were taken 
using the image analysis software “AxioVision LE” and AxioCam MRc camera (Carl 
Zeiss). Fruiting body aggregate morphology of MCy1366T was also studied by field 
emission scanning electron microscopy using a Zeiss Merlin, aldehyde fixed, critical-
point dried and gold palladium sputtered samples. Images were taken with the 
Everhart-Thornley SE-detector and Inlens-SE detector in a 25:75% ratio applying the 
SEMSmart software version 5.05.  Formation of myxospore-like structures by strain 
MCy1366T was observed in myxo media broth (10 g casein peptone, 1 mg CoCl2, 
0.05 g CaCl2·2H2O, 0.25 g MgSO4·7H2O, 23.6 g HEPES, 1 litre distilled water, pH 
7.0) after incubation for at least 3 days.  
The swarm colony of both isolates on VY/2 agar was transparent, soft, thin, and 
surrounded by a clear halo, owing to the lysis of yeast cells as often described for 
most members of Myxococcaceae (Reichenbach, 2005) but the salmon orange color 
of the MCy1366T cells was evident upon scraping the swarm with the loop. Swarm 
colony on P agar was yellow to orange colored with large flame-like outward 
extensions at the periphery (Fig.C1d) and surrounded by a clear halo suggesting 
starch hydrolysis. Swarm on CY agar was with shades of orange to brown color 
(Fig.C1b), ripples and flat ridges like structures in the center and intricate wavy veins 
at the edges (Fig.C1c). Such an undulating vein structure is typical for 
Myxococcaceae swarms on peptone containing agar (Reichenbach, 2005). Radiating 
veins in the swarm or corrosion of agar, typical for Cystobacteraceae and 
Nannocystaceae, respectively, were not observed on any medium.  
Vegetative cells were slender rods with slight tapering ends, mostly measuring 0.72-
0.82 µm x 5.71-10.73 µm except few which were as long as 20 µm upon cultivation in 
myxo media for 2 days (Fig.CS1b). Numerous optically refractile, irregular spherical 
to ellipsoidal myxospore-like structures (1.3-1.7 µm in size) surrounded by a 
conspicuous dark capsule were observed in the same media after longer (10-20 





days) incubation period (Fig.C1h). Cultivation in CY/H and myxo media broth 
displayed salmon orange and beige color of the vegetative cells of MCy1366T and 
MCy10622, respectively, which often gathered into a huge aggregate of cells. Such a 
massive aggregation of cells often into a single clump with a branching morphology 
pattern is a peculiar characteristic of both isolates in liquid media (Fig.C1a). 
Fruiting bodies like aggregates of MCy1366T could only be observed on P and CY 
agar after prolonged incubation (8-10 weeks) (Fig.C1e). They mostly appeared 
solitary as yellowish orange spherical heads and lacked sporangioles and stalk. 
Immature fruiting bodies had the appearance of humps or knobs on the agar, as in 
Myxococcus spp. (Reichenbach, 2005). Cell aggregation on the agar, presumably in 
an attempt to form the fruiting bodies was clearly visible under stereomicroscope as 
well as by scanning electron microscopic imaging (Fig.C1g). No fruiting bodies were 
observed on buffered VY/2 agar, while the new isolate MCy10622 could form 
reproducible fruiting bodies on the same agar within one week of incubation 
(Fig.C1f). However, the fruiting bodies of MCy10622 were irregularly shaped, cushion 
like cell mounds formed in groups clearly distinguishing themselves from MCy1366T 
fruiting bodies (Fig.C1f). Myxospores similar to spherical structures observed in liquid 
myxo media were also observed upon teasing of fruiting bodies and fruiting body like 
aggregates on a glass slide. 
Reaction of 3 week old swarm colonies of MCy1366T and MCy10622 on VY/2 agar to 
Congo Red stain was determined using the method of McCurdy (McCurdy, 1969). 
Enzyme activity was determined using APIZym strips (BioMérieux) inoculated with 
the cells grown in CY/H broth and further diluted with sterile water (1:10) and 
incubated aerobically at 30°C overnight. Starch hyd rolysis, cellulose and agar 
degradation was studied as described by Mohr et al. (2011). The chitin degradation 
assay was performed using CT-6 (Reichenbach, 2006) and synthetic S agar (0.5 g 
CaCl2.2H2O, 0.5 g MgSO4.7H2O, 0.06 g K2HPO4, 8 mg Ferric EDTA, 50 mM HEPES, 
1 liter distilled water, pH 7.2) with 0.7% (w/v) chitin as the sole nutrient source. Salt 
tolerance to 1.5% (w/v) sodium chloride was tested on CY agar after incubation for 3-
4 weeks at 30°C.  






Fig.C1. Photographs showing morphology of strain MC y1366T and MCy10622. (a) Photograph of huge bright orange  
cell aggregate of MCy1366 T in 11 day old culture in CY+H broth. (b) Saffron o range coloured 4-week-old swarming 
colony of MCy1366 T on CY agar. Stereophotomicrograph of (c) 4-week-ol d swarm of MCy1366 T on CY agar (bar, 2000 
µm),  (d) 3 week old swarm of MCy1366 T on P agar (bar, 2000 µm), (e) fruiting body-like a ggregates of MCy1366 T on P 
agar (bar, 500 µm), (f) mature fruiting bodies of M Cy10622 on VY/2 agar (bar, 200 µm). (g) SEM image s howing cell 
aggregation of MCy1366 T on agar surface for initiation of fruiting body fo rmation (bar, 20 µm) (h) Phase contrast image 
of myxospore-like structures in liquid myxo media ( bar, 20 µm)  
 





The Congo Red reaction was very weak and displayed light pink color (Fig.CS1a) in 
contrast to strong reactions observed for Corallococcus spp., Pyxidicoccus sp., and 
some Myxococcus spp. Both the isolates could not degrade cellulose, chitin or agar. 
No cell growth was observed for MCy1366T and MCy10622 under 1.5% NaCl 
concentration same as observed for Corallococcus spp. and Melittangium lichenicola 
while fair to good growth was observed for Pyxidicoccus fallax and all Myxococcus 
spp. except M. fulvus (Table CS2). The colorless haloes on P agar plate after 
staining with Lugol’s solution was limited to the size of MCy1366T and MCy10622 
swarms as opposed to Corallococcus spp. depicting weak starch hydrolysis ability 
(Fig.CS1c). Ability to degrade starch and salt tolerance are often used as 
characteristics to differentiate between species of Myxococcus and Corallococcus 
(Lang and Stackebrandt, 2009).  
The reactions on the APIZym strips by MCy1366T were reasonably similar to the 
reactions observed for Corallococcus spp. suggesting close relationship between 
both (Table CS3). Alkaline phosphatase, esterase lipase, leucine arylamidase and 
acid phosphatase were positive and ß-galactosidase, α-mannosidase and α-
fucosidase were negative for MCy1366T along with all the other strains used during 
this study (Table CS1). Trypsin was negative for MCy1366T along with Corallococcus 
spp. and M. lichenicola while it was positive for three Myxococcus spp. and P. fallax. 
All the reactions for MCy1366T on APIZym strips were same to the reactions from 
MCy10622 except cysteine arylamidase which was found to be negative for the 
former and positive for the latter. All these similar reactions observed for all the 
members of the family Myxococcaceae strengthened the supposition that both new 
isolates belong to the same family. Detailed results from the APIZym test system for 
all strains are given in supplementary information (Table CS3). 
Cross streaked microbial baits of live bacteria (Paenibacillus polymyxa DSM 36T), 
yeasts (Candida albicans DSM 1665, Wickerhamomyces anomalus DSM 6766) and 
autoclaved E. coli K12 cells on water agar was used for testing the ability of 
MCy1366T and MCy10622 to lyse microorganisms as described by Mohr et al. 
(2011). E. coli and C. albicans cells were completely lysed by both the strains. W. 
anomalus and P. polymyxa supported the growth of MCy1366T on water agar but 





clearing of cells could not be observed, making it difficult to assess the ability of 
MCy1366T to lyse the cells of these organisms. 
Growth response of MCy1366T and MCy10622 to different temperatures was tested 
at 20°C, 30°C, 37°C and 42°C on VY/2 agar. The pH o ptima for both strains were 
tested between pH 5.0 to 10.0 at intervals of 0.5 pH units in CY liquid media. 
Optimum growth temperatures for MCy1366T and MCy10622 were near 30°C like 
most myxobacteria. Both isolates could not grow at 42°C. They tolerated wide range 
of pH 6.0-10.0 but the maximum growth was seen at pH 6.5-7.0 (Table CS8). No 
evidence of growth was found below pH 5.5. 
Antibiotic resistance of strains MCy1366T and MCy10622 was tested along with the 
other related strains as described by Mohr et al. (2011) against 13 antibiotics. The 
final concentration was adjusted to 50 (µg ml-1) for most antibiotics except 
oxytetracycline (10), chloramphenicol (30), ampicillin (100) and hygromycin B (150). 
MCy1366T was sensitive to spectinomycin, thiostrepton and chloramphenicol and 
resistant to cephalosporin C, kanamycin, gentamycin, hygromycin B, polymyxin and 
bacitracin similar to the Corallococcus spp. used in this study. However, it was 
sensitive to fusidic acid and ampicillin as opposed to the Corallococcus spp. which 
showed little growth on fusidic acid but good growth on ampicillin. MCy10622 was 
found to be sensitive to spectinomycin and thiostrepton whereas resistant to most of 
the other antibiotics tested. MCy1366T and MCy10622, both grew poorly on 
trimethoprim. A detailed description of the antibiotic resistance test is given in the 
supplementary information (Table CS4). 
Synthetic liquid medium S containing 0.25% (w/v) casitone and supplemented with 
0.25% (w/v) of various sugars and starch was used for testing the carbon sources 
favored for growth. Nitrogen requirement was tested on a minimal casitone medium 
(C) (Mohr et al., 2011) with addition of 0.25% (w/v) of some organic and inorganic 
nitrogen sources. Utilization of various peptones was also tested by addition to 
synthetic S medium individually at a concentration of 0.25% (w/v). These 
experiments were performed in duplicates and all flasks were incubated at 30°C, 200 
rpm for 7 days. Cell pellets were collected and washed with sterile water in order to 





Table C1. Differential characteristics of strain MC y1366T, MCy10622 and their closely related strains 
Features Myxococcus spp. Corallococcus spp. MCy1366T MCy10622 Pyxidicoccus fallax 
Melittangium 
lichenicola 
No. of strains used for study 5 2 
 
 1 1 
Resistance to:    
   
Ampicillin (100ug/ml) V(3) + - + + - 
Kanamycin (50ug/ml) V(2) + + + - + 
Spectinomycin (50ug/ml) + - - - + + 
Trimethoprim (50ug/ml) V(2) + + + + + 
Fusidic acid (50ug/ml) V(3) + - + + - 
Growth at 1.5% salt V(4) - - - + - 
Starch hydrolysis Weak positive Strong positive Weak positive Weak positive Positive n.i. 
Congo red reaction Weak/Strong Strong Very weak Very weak Strong Weak   
ApiZym Test    
   
Trypsin V(3) - - - + - 
Fatty acid analysis    
   
C15:0 0.0-2.7 0.2-0.8 1.8 1.6 1.1 0 
C15:1 isomer 2 0.0-2.5 0.1-0.4 3.3 0 0.9 0 
C16:1isomer 2 6.1-14.5 0.2-0.6 1.1 0 21.0 5.5 
C17:1ω7cis 0.0-1.0 1.5-2.2 0.40 0 0.2 0 
iso C15:0 13.5-39.7 17.5-22.3 23.2 25.3 14.0 13.0 
iso C17:0 1.3-11.7 4.3-10.1 16.6 10.4 7.7 0.8 
iso C17:0 2-OH 0.2-12.4 32.9-34.4 26.1 14.1 9.3 0.5 
iso C15:0 OAG 0.0-10.3 3.4-7.2 1.9 1.3 2.9 0 
iso C15:0 DMA 0.0-2.1 1.6-4.2 2.0 4.4 4.7 0 
* Results for individual strains are given in Supplementary Tables S2, S3, S4 and S7. V, Variable results (numbers of positive strains given in parentheses); n.i., not determined; for reactions to antibiocs, + (positive) indicates 
resistance, growth; and – (negative) indicates sensitivity, inhibition of growth; fatty acids analysis, isomer 2, position isomer of a monounsaturated fatty acid; ω7cis, Omega-7 fatty acid with cis double bond; 2-OH, Hydroxy 
fatty acid; OAG, O-alkylglycerol fatty acids; DMA, Dimethylacetal fatty acids. Strain used for the study: Myxococcus spp. (M. xanthus DSM 16526T, M. fulvus DSM 16525T, M. stipitatus DSM 14675T, M. virescens DSM 
2260T, M. macrosporus DSM 14697T); Corallococcus spp. (C. exiguus DSM 14696T, C. coralloides DSM 2259T); Pyxidicoccus fallax DSM 14698T and Melittangium lichenocola DSM 2275T. 





MCy1366T as well as MCy10622 could not utilize any of the monosaccharides or 
disaccharides under the tested conditions (Table CS5). This is also true for most of 
the members of the family Myxococcaceae (Reichenbach, 2005). However, growth 
was observed on molasses (Juchem) which could be due to presence of other 
supplements. They could utilize polysaccharides viz. potato starch, soluble starch 
and pyruvate. But the two strains differ slightly in their peptone requirements. Strain 
MCy1366T yielded high cell densities in neopeptone (Becton Dickinson), phytone 
peptone (BD) and skimmed milk (Oxoid) whereas MCy10622 grew better in tryptone 
enzymatic digest from casein (BD). No growth was observed in synthetic media S 
supplemented with casamino acids (BD). All the organic and inorganic nitrogen 
sources tested resulted in moderate to fair growth of both the strains (Table CS6). 
For fatty acid analysis, all the strains used in the study (Table CS7) were cultivated in 
50 ml of CY medium in 300 ml flasks shaken at 160 rpm at 30ºC. Cellular fatty acid 
extraction, GC-MS analysis and peak identification was done in duplicates using the 
method described by Garcia et al. (2011). All the strains had substantially high 
amounts of iso-C15:0, which is true for most myxobacteria (Garcia et al., 2009). The 
fatty acid pattern of strains MCy1366T and MCy10622 was significantly distinct from 
all the other strains used in the study. Strain MCy10622 differed from MCy1366T 
because of the presence of significant amounts of iso-C17:1 (10.9 %) while it was 
completely absent in the fatty acid profile of the latter. Strain MCy1366T showed 
highest percentage of the branched chain fatty acid, iso-C17:02-OH (26.1%) followed 
by iso-C15:0 (23.2%) (Table C1). Indeed, high amounts of iso-C17:02-OH has been 
recommended as a determinative chemotaxonomic marker for Corallococcus spp.  in 
the family Myxococcaceae (Garcia et al., 2011). Strain MCy1366T possessed a 
significant amount of iso-C17:0 (16.6 %) and higher amounts of C15:1 isomer2 (3.3%) 
compared to all the other strains. MCy1366T also differed from Corallococcus spp. 
because of the lower amounts (1.9%) of O-alkylglycerol (OAG) FAs. In addition, 
MCy1366T and MCy10622 clearly distinguished from M. lichenicola DSM 2275T 
because of the presence of much higher amounts of C16:0 (9.8%), C18:0 (20.6%) and 
unspecified fatty acid alcohol (32.1%) as well as much lower amounts of iso-C15:0 
(13.0%) and iso-C17:02-OH (0.5%) in the latter compared to the former two strains. 
The total amount of SCFAs and BCFAs for strain MCy1366T was 15.4% and 84.4%, 





respectively, while MCy10622 showed 10.0% and 76.3% of total SCFAs and BCFAs, 
respectively (Table CS7). 
For 16S rRNA gene amplification, genomic DNA was extracted from actively growing 
cells of MCy1366T and MCy10622 using the protocol for gram-negative bacteria of 
the Puregene CoreKit A (Qiagen). 16S rRNA gene was amplified by PCR using 
universal primers (forward 5’-GAGTTTGATCCTGGCTCAGGA-3’; reverse 5’-
AAGGAGGTGATCCAGCCGCA-3’). The PCR product was purified using Nucleospin 
Gel and PCR clean-up (Macherey Nagel) following analysis of PCR product by gel 
electrophoresis using 0.8% (w/v) agarose gel at 95 V for 35 min. The same set of 
primers along with forward primers F27, F945, F357, F1100 and reverse primers 
R336, R518, R1078 and R1525 was applied for sequencing of the 16S rRNA gene 
(Lane, 1991; Turner et al., 1999; Stackebrandt and Liesack, 1993; Weidner et al., 
1996). The consensus sequences were produced using the Cap contig assembly 
function of the BioEdit Sequence Alignment Editor Version 7.1.3.0. and compared to 
the NCBI-BLAST nucleotide data bank using FASTA search tool and showed highest 
similarity (MCy1366T, 97.60%, and MCy10622, 97.47%) to invalidly described taxon, 
“Stigmatella koreensis” strain KYC-1019 (GenBank accession no. EF_112185). 
The complete sequences of MCy1366T and MCy10622 were aligned with sequences 
of their close relatives using ClustalW (Larkin et al., 2007). A phylogenetic analysis 
with type and representative myxobacterial strains was calculated using two tree-
making algorithms; neighbor joining (Saitou and Nei, 1987) and maximum likelihood 
(Guindon and Gascuel, 2003) methods by using the software package Geneious 
7.0.3 version (Biomatters, New Zealand). A sulfate-reducing bacterium, Desulfovibrio 
desulfuricans DSM 642T (GenBank accession no. NR_036778) was chosen as an 
out-group to root the phylogenetic tree. Jukes Cantor model (Jukes and Cantor, 
1969) was applied to calculate evolutionary distance matrices of the neighbor joining 
and maximum likelihood method. The topology of the phylogenetic tree was 
evaluated by bootstrap support based on 1000 resamplings (Felsenstein, 1985).  
The tree constructed by maximum likelihood (Fig. C2) method showed that both 
strains (MCy1366T and MCy10622), formed a separate cluster within the family 
Myxococcaceae close to C. exiguus DSM 14696T, C. coralloides DSM 2259T and 
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Melittangium lichenicola DSM 2275
myxobacterial taxa in the suborder 
phylogenetic tree constructed with the neighbor joining method (Fig.
delineation of the two isolates from closely related strains and clustering within 
Myxococcaceae, clearly indicate that they represent a new taxon in the same family.
Fig.C2. Maximum likeliho od phylogenetic tree (PHYML) based on 16S rRNA gene  sequences of strains MCy1366
MCy10622 and related taxa. Numbers at the branch po ints indicate bootstrap support based on 1000 resam plings. Bar, 
0.05 substitutions per nucleotide position. The Gen Bank
parentheses. Desulfovibrio desulfuricans
The two closest relatives of MCy1366
gene sequence-based phylogenetic tree
DSM 2259T were chosen for DNA
content analysis. A method adapted from Kieser 
Aggregicoccus edonensis gen. nov. sp. nov.
 
T. Their separate branching from the known 
Cystobacterineae was also clear in the 
 accession number of strains used in the tree is sho wn in 
 DSM 642T was used as an outgroup.  
T and MCy10622 according to the 16S rRNA 
, C. exiguus DSM 14696T and 
-DNA hybridization assay and DNA G+C mol% 













optimized especially for myxobacteria was used for isolation of high yields of genomic 
DNA. 100 ml cultures in myxo media, CY+H media and A media (8 g starch, 4 g 
soymeal, 2 g yeast, 1 g CaCl2, 1 g MgSO4, 100 mM HEPES, 8 mg Ferric EDTA, 4 ml 
glycerol, 1 liter distilled water, pH 7.4), respectively, were harvested by centrifugation 
at 12000 rpm for 5 min. The cell pellets were re-suspended in 10 ml Tris buffer after 
discarding the supernatant. The cell aggregates were dispersed and homogenized 
with an Ultraturrax (Art Moderne Labortechnik). After addition of 200 µl proteinase K 
(20 mg ml-1 in 50 mM Tris–HCl, 1 mM CaCl2.2H2O, pH 7.5) and 200 µl SDS (20% 
(w/v) solution), the solution was mixed gently and kept in hybridization oven for 
continuous shaking and incubation at 41°C for 30 mi n–2 hrs until the solution 
became slightly clear. 3.5 ml of 5 M NaCl was added to the solution with gentle 
mixing followed by 4 ml CTAB extraction buffer (4.1% (w/v) NaCl, 10% (w/v) Cetyl 
trimethylammonium bromide, water). The cell solutions were again shaken and 
incubated at 65°C for another 20 min inside the hyb ridization oven. The cell solution 
was incubated at room temperature from 1 hr to 12 hrs in an overhead shaker after 
addition of chloroform up to 35 ml. Phase separation of the solution was then 
achieved by centrifugation at 12000 rpm for 20 min and the upper phase was 
carefully transferred into new falcon tubes. The acquired upper phase was mixed with 
equal volume of isopropanol and mixed gently. The precipitated DNA was aspirated 
and rinsed with 70% (v/v) ethanol twice. DNA was then air dried and dissolved in 2 ml 
TE buffer.  
DNA-DNA hybridizations (DDH) was performed as described by Ziemke et al. (1998), 
with the modification that for nick translation, 2 µg of DNA was labeled during a 3 hr 
incubation at 15°C. The G+C mol% was determined usi ng a fluorimetric thermal 
denaturation temperature determining method described by Gonzalez & Saiz-
Jimenez (2002). Analysis was performed in a total volume of 20 µl, including 5 µg 
genomic DNA, 0.1X SSC buffer (0.03 M NaCl, 0.03 M sodium citrate), 10% (v/v) 
deionized formamide and 0.25X SYBR Green I (Molecular probes). Thermal 
denaturation was performed in a CFX384 Touch™ Real-Time PCR Detection System 
(BioRad) starting with 15 min at 25°C, followed by a ramp from 65 to 98°C with an 
increase of 0.1°C cycle -1. Each cycle holds for 5 s including a fluorescence 
measurement (SYBR channel). Analysis was performed at least in duplicates. Five 





reference strains were used to generate a standard curve of G+C mol% versus 
melting temperature (Tm). A linear regression analysis was used to calculate the 
G+C mol%. 
The DNA G+C content of strain MCy1366T was found to be same as Corallococcus 
coralloides DSM 2259T i.e. 65.6 mol% in our analysis. The type strains of C. exiguus 
DSM 14696T and C. coralloides DSM 2259T are very closely related species with 
99.9% 16S rRNA gene sequence similarity and sharing 61.5% DNA-DNA similarity 
(Stackebrandt et al., 2007). However, these high values did not hold true for the pairs 
MCy1366T and DSM 14696T (28%; with 97% 16S rRNA gene sequence similarity) 
and MCy1366T and DSM 2259T (35.15%; with 96.9% 16S rRNA gene sequence 
similarity) clearly revealing that strain MCy1366T does not belong to C. exiguus or C. 
coralloides (Wayne et al., 1987). MCy1366T and MCy10622 showed 99.9% 16S 
rRNA gene sequence similarity and 100% DNA-DNA similarity. 
Biomass for matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) analysis was collected from one week old, 100 ml 
cultures of MCy1366T, MCy10622 and the reference strains in CY+H broth, 
centrifuged at 12000 rpm for 10 min. Whole-cell protein extracts were analyzed by 
using a Microflex L20 mass spectrometer (Bruker Daltonics) equipped with a N2 
laser. Sample preparation for MALDI-TOF MS protein analysis was carried out 
according to the ethanol/formic acid extraction protocol recommended by Bruker 
Daltonics as described in detail by Tóth et al. (2008). The MALDI-TOF mass spectra 
were analyzed with the BioTyper software (version 3.1, Bruker Daltonics). The 
dendrogram generated on the basis of MALDI-TOF mass spectra (Fig. C3) confirms 
the close relationship of the strains MCy1366T and MCy10622 as revealed by DNA-
DNA hybridization and demonstrates that both strains can be differentiated by 
MALDI-TOF MS from related type strains of the genera Corallococcus, Myxococcus, 
Pyxidicoccus and Melittangium.  
In addition to the 3% phylogenetic distance based on 16S rRNA gene sequences and 
low DNA-DNA relatedness to the closest known myxobacterial neighbors (C. exiguus 
and C. coralloides); strain MCy1366T also delineates into a novel branch in the 
MALDI-TOF MS dendrogram, show distinct cellular fatty acid profile and biochemical 
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characteristics compared to other members of 
propose strain MCy1366T 
nov., and a new species 
distinguishing characteristics.
Fig.C3. Score- oriented dendrogram generated by the BioTyper softw are (version 3.1, Bruker Daltonics) showing the 
similarity of MALDI- TOF mass spectra of cell extracts of strains MCy136 6
species within the genera Corallococcus, Myxococcus, Pyxidicoccus
C.4. Description of Aggregicoccus 
Aggregicoccus gen. nov. (Ag.gre.gi.cocc'us. Lat. v. aggrego, to aggregate, form 
clumps; N.L. masc. n. coccus
masc. n. Aggregicoccus, an aggregating coccus 
cells in liquid culture) 
The vegetative cells are rod
Transparent swarms on VY/2 yeast 
intricate veins on edges on CY agar
stain. Fruiting bodies like aggregates and fruiting bodies are spherical to irregularly 
shaped, cushion like, yellow orange color
Myxospores are optically refractive, irregularly spherical.  Myxospore
Aggregicoccus edonensis gen. nov. sp. nov.
 
Myxococcaceae.
as a representative of a new genus Aggregicoccus
Aggregicoccus edonensis sp. nov 
 
T, MCy10622 and type strains of related 
 and Melittangium. 
gen. nov.  
 (from Gr. masc. n. kokkos, grain, seed, coccus); N.L. 
referring to massively aggregating 
-shaped with slight tapering ends (Myxococcaceae
agar. Produce wavy, rippling structures with 
. Colonies are very weak positive in Congo Red 
ed, lacking sporangioles and stalks. 
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are also produced in peptone containing liquid media upon longer incubation. Does 
not utilize monosaccharides and dissacharides. Bacteria and yeast are lysed. 
Aerobic, chemoorganotrophic and strictly mesophilic. Hydrolyses starch, but not 
cellulose, chitin or agar. The G + C content is 65.6 mol%. The phylogenetic position 
is in the family Myxococcaceae, suborder Cystobacterineae, Order Myxococcales. 
The type species is Aggregicoccus edonensis. 
C.5. Description of Aggregicoccus edonensis sp. nov.  
Aggregicoccus edonensis (e.do.nen’sis. N.L. masc. adj. edonensis, belonging to Edo, 
former name of Tokyo, where the soil sample was collected from which the type 
strain was isolated). 
In addition to the characteristics of the genus, the vegetative cells are 0.72-0.82 µm x 
5.71-10.73 µm in size. The swarm colony varies from yellow orange to almost 
transparent color depending upon the medium. Myxospore-like structures, 1.3-1.7 µm 
in size and covered with outer capsule were obtained in liquid media. Cell aggregates 
are beige to saffron orange in color with extreme branching in peptone or casitone 
media. Growth optimal temperature is between 30°C a nd 37°C. pH tolerance is 
between 6.0–10.0, and optimum at 6.0-7.0. Cannot tolerate high salt concentrations. 
Best nutritional sources are media with peptones. Can utilize L-asparagine 
monohydrate, ammonium sulfate, potassium nitrate, urea, L- glutamic acid, glycine, 
L-lysine monohydrate and L-arginine as nitrogen sources in the presence of casitone. 
Major fatty acids are C17:0 2-OH, iso-C15:0 and iso-C17:0. Alkaline phosphatase, esterase 
lipase, leucine arylamidase and acid phosphatase production was positive while ß-
galactosidase, α-mannosidase and α-fucosidase showed negative reaction in 
APIZym test system. The type strain is MCy1366T (=DSM 27872T, =NCCB 100468T), 
isolated from soil collected in 1981 from a region near Tokyo, Japan. 
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Table CS1. Type and neotype strains used in this st udy 
Strain name Strain no.  
Corallococcus exiguus DSM 14696T (Cc e167T) 
Corallococcus coralloides DSM 2259T (M2T) 
Myxococcus virescens DSM 2260T (M22T) 
Myxococcus fulvus DSM 16525T (M17T) 
Myxococcus xanthus DSM 16526T 
Myxococcus stipitatus DSM 14675NT (Mx s8NT) 
Myxococcus macrosporus DSM 14697 T (Cc m8T) 
Pyxidococcus fallax DSM 14698T (Py f1T) 
Melittangium lichenicola DSM 2275T (M155T) 
 
 
Table CS2. Salt tolerance   
Strain name Growth on CY agar with 1.5% NaCl (w/v) 
MCy1366T  - 
MCy10622 - 
C. exiguus DSM 14696T - 
C. coralloides DSM 2259T - 
M. virescens DSM 2260T +++ 
M. fulvus DSM 16525T - 
M. xanthus DSM 16526T ++ 
M. stipitatus DSM 14675NT + 
M. macrosporus DSM 14697NT +++ 
P. fallax DSM 14698T + 
M. lichenicola DSM 2275T - 
































Control C C C C C C C C C C C 
Esterase(C4) + + + + + V + - + + + 
Lipase(C14) - + + - + + + + + + + 
Valine arylamidase 
 + + + + + + + + - - + 
Cystine arylamidase + + + + - - + + - - + 
Trypsin + - + - + - - - - + - 
α-chymotrypsin 




- + + + + + + + + + + 
α-galactosidase 
 
- - - + - - - - - - - 
ß-glucuronidase 
 - - - + - - - - - - - 
α-glucosidase 
 - - - + - - - - - - + 
ß-glucosidase - - - + - - - - - - - 
N-acetyl-ß-
glucosaminidase + - - + - - - - - - + 
Reactions on APIZym strips: +, positive; -, negative; V, variable. All the tested strains were positive for alkaline phosphatase, esterase lipase, leucin arylamidase, and acid phosphatase and negative for ß-galactosidase, α-






Table CS4. Antibiotic resistance test for MCy1366 T and MCy10622 along with related type and neotype s trains 
+, Growth; -, Inhibition of growth; n.c., not clear. All the tested strains were resistant to cephalosporin C, gentamycin, hygromycin B and polymyxin.  
Antibiotic M. stipitatus
                      
DSM 14675NT 
M. virescens               
DSM 2260T 
















agar + + + + + + + + + + + 
Ampicillin + - + - + - + + + + - 
Kanamycin + - - + - + + + + - + 
Spectinomycin + + + + + - - - - + + 
Trimethoprim + - - - + + + + + + + 
Bacitracin + + + + + + + + + + - 
Oxytetracyclin - - - - - - n.c. - - - - 
Fusidic acid + + + - - - + + + + - 
Thiostreptone + - - - - - - - - + - 
Chloramphenicol - + - - - - n.c. - - + - 





Table CS5. Dry weight biomass (mg) of MCy1366 T and MCy10622 obtained in synthetic S medium with c asitone 
supplemented with various carbon sources.  
 
Table CS6. Dry weight biomass (mg) of MCy1366 T and MCy10622 in minimal casitone (C) medium with v arious 
inorganic nitrogen sources, amino acids or peptones  sources. 
Carbon sources Average dry biomasses (MCy1366T) Average dry biomasses (MCy10622) 
1. Sucrose  16.05 14.25 
2. Fructose 15.15 16.0 
3. Maltose 14.15 16.7 
4. Potato starch 41.05 43.85 
5. Molasses 29.95 29.85 
6. Xylose 15.05 14.4 
7. Soluble starch 29.6 31.35 
8. Cellobiose 16.1 15.2 
9. Lactose 16.35 17.25 
10. Mannose 14.35 15.35 
11. Galactose 20.5 14.75 
12. Glucose 15.45 15.0 
13. Pyruvate 20.2 25.35 
14. Control 15 14.25 
Nitrogen sources Average dry biomasses 
(MCy1366T) 
Average dry biomasses 
(MCy10622) 
1. L-asparagine monohydrate 16.7 24.55 
2. Urea 15.6 15.55 
3. L-arginine 13.25 19 
4. KNO3 13.25 12.5 
5. (NH4)2SO4 11.5 14.85 
6. L-lysine monohydrate 14.8 14.5 
7. Glycine 12.7 12.45 
8. L-glutamic acid 15.3 24.35 
9. Probion FM 582 61.1 60.65 
10. Tryptone enzymatic digest of casein 7.9 20.35 
11. Casitone 19.75 25.75 
12. Soytone 23.4 13.9 
13. Yeast extract 13.4 21.15 
14. Tryptone 18.95 33.05 
15. Neopeptone 9.1 4.15 
16. Phytone peptone 10.75 3.1 
17. Skimmed milk 16.3 7.3 
18. Gluten from wheat 32.85 39.6 
19. Corn Steep solid 28.65 83.45 
20. Meat extract 15.25 14.7 
21. Casamino acid 1.5 1.4 


























SCFAs            
C10:0 - - - - 0.2 0.3 - 0.3 0.2 0.1 - 
C11:0 0.2 - - 0.1 - - - 0.1 - - - 
C12:0 0.0 - - - 0.1 0.1 - - - - - 
C13:0 0.1 - - - - 0.2 - 0.1 0.1 - - 
C14:0 - - 0.1 - 5.4 6.4 0.2 3.5 2.2 0.8 - 
C15:0 0.8 0.2 1.8 1.6 2.7 2.5 - 2.5 2.7 1.1 - 
C16:0 1.6 1.5 2.4 0.5 4.1 4.3 8.2 4.1 4.1 6.1 9.8 
C17:0 0.2 - 0.5 0.4 - - - 0.1 - 0.3 - 
C18:0 3.7 3.7 4.9 0.5 5.8 4.6 14.1 1.5 5.8 4.1 20.6 
C14:1 isomer 1 - - - - 1.8 0.5 - 0.5 - - - 
C14:1 isomer 2 - - - - 0.1 0.1 - 0.2 0.2 0.7 - 
C14:1 isomer 3 - - - - 0.3 0.1 - 0.1 - - - 
C15:1 isomer 1 0.3 0.3 - 4.3 1.9 1.1 - 1.0 0.1 - - 
C15:1 isomer 2 0.4 0.1 3.3 - 2.5 1.7 - 1.9 0.5 0.9 - 
C16:1 isomer 1 - - - 1.6 0.5 0.8 8.6 0.6 0.4 - 3.3 
C16:1 isomer 2 0.6 0.2 2.0 - 7.9 12.6 6.1 13.6 14.5 21.0 5.5 
C17:1 isomer 1 - - - 0.7 - - - - - - - 
C17:1ω7cis 1.6 2.2 0.4 - - - - 1.0 - 0.2 - 
C18:1 0.1 - - 0.1 - - - - 0.2 - - 





C16:2 - - - - 3.4 3.5 - 3.0 0.6 - - 
C18:3w6,cis9,12 - - - 0.2 - - - - - - - 
Hydroxy FAs            
C13:0 3-OH - - - - - - - - - - - 
C14:0 3-OH - - - - 0.4 0.7 - 0.5 0.6 0.6  0.1 
C15:0 3-OH - - - - 0.1 0.1 0.3 0.1 0.1 - - 
C16:0 2-OH - - - - 0.2 1.1 - 0.2 0.7 1.2 - 
C16:0 3-OH - - - - 0.4 0.6 0.5 0.3 0.6 0.4 0.2 
C16:1 3-OH - - - - - - - - - 0.2 - 
C24:0 2-OH - - - - - - - - - - - 
Total SCFAs 9.6 8.2 15.4 10.0 37.8 41.3 38.0 35.2 33.6  37.7 39.5 
BCFAs            
iso-C13:0 1.9 0.8 0.2 1.5 0.7 0.4 - 0.5 0.2 0.1 - 
iso-C14:0 0.7 0.3 - 0.4 - - -  0.1 - - 
iso-C15:0 17.6 22.3 23.2 25.3 39.8 34.5 13.5 30.7 16.3 14.0 13.0 
iso-C15:1 - - - 1.0 - - - - - - - 
iso-C15:1ω9cis - 1.1 -  0.8 - - 0.4 - - - 
iso-C16:0 1.9 1.4 2.6 3.3 0.1 0.8 0.2 0.4 1.1 0.9 0.1 
iso-C16:1 - 1.1 - 0.4 - 0.3 - 0.1 - - - 
iso-C17:0 10.1 4.3 16.6 10.4 3.3 3.2 1.4 8.1 11.8 7.7 0.8 
iso-C17:1 - - - 10.9 - - - - - - - 
iso-C17:1ω5cis 12.8 8.2 9.5 - 1.9 1.2 7.3 2.9 2.5 1.9 6.1 
iso-C17:1ω11cis - 2.0 0.2 - 0.7 0.5 - - 0.3 - - 
iso-C17:2 - - - 2.3 - - - - - - - 





anteiso-C15:0 - - 0.3 0.3 - - 6.0 0.2 - - 0.8 
anteiso-C17:0 
 
0.1 - 0.4 - - - - 0.1 - - - 
Branched-chain hydroxy 
FAs 
         
iso-C15:0 3-OH 2.8 1.6 1.2 0.7 3.1 3.3 4.4 2.9 3.5 1.9 2.7 
iso-C16:0 2-OH 0.1 0.2 0.1 - - - - - - - - 
iso-C16:0 3-OH - - - - - - - - - - - 
iso-C17:0 2-OH 34.4 33.0 26.1 14.1 4.2 7.1 0.2 3.3 12.4 9.3 0.5 
iso-C17:0 3-OH 0.3 - 0.1 - 1.2 1.3 3.7 1.2 1.1 0.4 3.2 
iso-C17:1 2-OH 0.0 - - - - - - - - - - 
Branched chain OAG FAs           
C14:0 - - - - - - - 0.1 0.3 0.4 - 
C15:0 - - - - - - - 0.1 - 2.9 - 
C16:0 - - - - - - - 0.1 0.4 7.4 - 
iso-C15:0 3.4 7.2 1.9 1.3 3.0 3.9 - 10.3 10.1 10.8 - 
Branched chain DMA 
FAs 
          
iso-C15:0 1.6 4.2 2.0 4.4 1.0 0.7 - 1.7 2.1 4.7 - 
Total BCFAs 88.7 91.4 84.4 76.3 62.2 58.1 36.7 64.5 62.3 62.4 27.2 
Fatty alcohols            
iso Pentadecanol 0.1 0.3 0.0 - - 0.0 0.8 0.0 0.2 0.0 0.9 
Hexadecanol - - - - - 0.0 0.0 - - - - 
Unspecified fatty alcohol - - - - - - 24.4 - - - 32.1 
(Abbreviations: SCFAs, Short chain fatty acids; PUFAs, Polyunsaturated fatty acids; BCFAs, Branched chain fatty acids; OAG Fas, O-alkylglycerol fatty acids; DMA Fas, Dimethylacetal f tty acids) 












































Fig.CS1. (a) Congo Red staining of 3 week old swarm  of strain MCy1366 T on VY/2 agar displaying a weak positive reaction 
(b) Phase contrast microscopic image of vegetative cells of MCy1366 T in myxo media (bar, 10µm) (c) Lugol’s solution 
staining of 2 week old swarm of strain MCy1366 T on P agar displaying a weak positive reaction.  
pH Average dry biomasses (MCy1366T) Average dry biomasses (MCy10622) 
5.0 0.10 0.25 
5.5 0.15 0.20 
6.0 34.30 27.50 
6.5 50.15 52.00 
7.0 41.40 38.05 
7.5 24.55 25.15 
8.0 12.35 21.30 
8.5 12.40 15.15 
9.0 11.55 14.50 
9.5 9.55 14.35 














Fig.CS2. Neighbor-joining tree bas ed on 16S rRNA gene sequence showing the phylogenet ic position of MCy1366
MCy10622. The numbers at branch points indicate boo tstrap support based on 1000 resamplings. Bar, 0.05  substitutions 
per nucleotide position. The GenBank accession numb er for ea




ch strain is shown in parentheses. 
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The chlorinated pyrrole-oxazole-pyrones, pyrronazol A (1), pyrronazol A2 (2) and 
pyrronazol B (3) were isolated from Nannocystis pusilla strain Ari7 as well as two 
chlorinated pyrrole-oxazole isomers, pyrronazol C1 (4) and C2 (5), from N. pusilla strain 
Na a174. HRESIMS, NMR, and X-ray crystallographic analysis was used in the 
structure elucidation including the absolute configuration of pyrronazol A (1). In addition 
to pyrronazols, 1,6-phenazine-diol (6) and its glycosyl derivative, 1-hydroxy-phenazine-
6-yl-α-D-arabinofuranoside (7) were isolated and identified from the culture broth of N. 
pusilla strain Ari7. When tested for biological activity against bacteria, fungi, and yeasts, 
1 showed weak antifungal activity against Mucor hiemalis (MIC 33.3 µg/mL) but no 
antibacterial activity, while 6 showed weak antibacterial and antifungal activity (MIC 33.3 
µg/mL) against some of the strains tested. In cell culture experiments 1 showed no 
significant cytotoxicity while 6 was active against several cell lines, especially the 
human ovarian carcinoma cells SK-OV-3 (LD50 2.59 µM).  
D.2. Introduction 
Myxobacteria have been used as a source of new natural products for almost three 
decades (Bode and Müller, 2007; Wenzel and Müller, 2009). In our quest to find 
valuable and structurally diverse natural products, we constantly engage in screening 
strains from our continuously expanding in-house collection of myxobacteria. 
Pyrronazols were identified from our screening program and isolated as novel 
secondary metabolites from strain Ari7. The 16S rRNA gene sequence analysis of the 
producing strain Ari7 showed 99.9% similarity to Nannocystis pusilla (DSM 14622T). 
Previously, N. pusilla strain B150 and N. exedens have been reported as producers of 
phenylnannolones, inhibitors of P-glycoprotein mediated efflux of drugs from eukaryotic 
cells (Ohelndorf et al., 2008). Further, the siderophores nannochelins (Kunze et al., 
1992), steroids (Kohl et al., 1983), germacrane (Reichenbach and Höfle, 2000) and 
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Herein, we report the isolation and structure elucidation of three secondary metabolites, 
pyrronazol A (1), pyrronazol A2 (2) and pyrronazol B (3) from Nannocystis pusilla, strain 
Ari7, as well as pyrronazol C1 (4) and C2 (5) from N. pusilla strain Na a174. Extensive 
HRESIMS, NMR, and X-ray crystallographic analysis was used for the structure 
elucidation of pyrronazol A (1). In addition to pyrronazols, 1,6-phenazine-diol (6) and its 
glycosyl derivative, 1-hydroxy-phenazine-6-yl-α-D-arabinofuranoside (7) were isolated 
and identified from the culture broth of N. pusilla strain Ari7.  
D.3. Results and Discussion  
For metabolite production N. pusilla, strain Ari7 was inoculated in a liquid medium 
supplemented with Amberlite XAD 16 resin and fermented in a 10 L bioreactor for 
7 days. The resin was recovered from the culture broth by sieving and the crude extract 
was eluted from the resin using methanol. The products were isolated from the crude 
extract using a series of solvent partitioning, silica gel chromatography, preparative RP-
MPLC and RP-HPLC, and thin layer chromatography. 
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Pyrronazol A (1) was isolated from both strains as crystals melting under decomposition 
at 150 °C. HRESIMS presented the molecular ion clus ters for [M+H]+ and [M+Na]+, and 
a prominent fragment ion [M-H2O]
+ in positive mode as well as [M-H]- in the negative 
mode, all pointing to the chlorine-containing elemental formula C17H17ClN2O5 with ten 
double bond equivalents. Accordingly, the UV spectrum displayed two chromophores at 
348 and 232 nm. All carbons and protons were visible in the 1D NMR spectra in CDCl3 
and those directly connected with each other were correlated by the 1H,13C HMQC 
spectrum defining the singlets at δH = 10.6 and 4.08 as NH and OH signals, 
respectively. The COSY NMR spectrum revealed only two small structural elements 
(Figure D1), i.e., methines H-4 and H-5 with methyl group C-16 and methines H-12 and 
H-13, which showed a long-range correlation to the NH signal. A further long-range 
correlation was observed between H-5 and H-7. Thus, the carbon skeleton was derived 
from the 1H,13C HMBC NMR data (Table D1) as illustrated in Figure D1. The connection 
of the chlorine atom was required from the elemental formula and the 13C chemical shift 
of the C-14 atom, while the closure of the 2-pyrone ring was mainly assigned due to the 
acyl shift of the oxymethine H-5 at δ 5.34 ppm. The ROESY NMR spectrum offered only 
a few correlations, although, the proximity of 2-H and the methoxy group C-15 as well 
as of methines H-10 and H-12 was indicated. The latter revealed the cis relative 
configuration of the substituted double bond and the pyrrole H-12. A supporting NOE 
effect was observed between H-17b and the NH signal on the opposite side. The 
absence of NOE effects between methylene C-17 and methine C-10 suggested the 
trans configuration of the ∆9,10 double bond, whereas the absence of an NOE effect 
between methine H-5 and methyl C-16 and methine H-7 required their H-5/C-16 trans 
configuration and a H-5/H-7 transoidal conformation of the 5,6-dihydro-2H-pyran-2-one 
ring, respectively. 
Since 1 could be crystalized from methanol, an X-ray crystal analysis was conducted. 
Fortunately the crystal was of real good quality to allow the determination of the 
absolute configuration from structure refinement (Flack x = -0.001(22) from 2103 
selected quotients (Parsons' method), which indicated the absolute 4S,5S-configuration 
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NH is caused by a hydrogen bond between 17-O and the pyrrole NH. The gross 





















Figure D1. Selected 1H,13C HMBC (green arrows) and ROESY NMR Correlations (r ed arrows) of Pyrronazol A (1). (bold 
bonds show vicinal COSY correlations)  
 
Figure D2. Absolute 4 S,5S-Configuration of Pyrronazol A (1) (red: O; blue: N ; green: Cl) 
Interestingly, as a byproduct from N. pusilla strain Ari7, an isomer 2 of C17H17ClN2O5 
was isolated showing the same HRESIMS molecular ion clusters as 1. The NMR data 
(Table D1) of pyrronazole A2 (2) suggested a similar carbon skeleton, though with a cis 
configuration of the methyl substituted ∆9,10 double bond, that was indicated by a strong 
ROESY correlation between methylene protons H-17 and H-10. While the correlation 
between H-10 and H-12 was still present, the ROESY correlation of methylene H-17b 
with the pyrrole NH was lost. As a consequence of the lost fixation by the hydrogen 
bond the methylene proton signals no longer appeared separated (∆δ ~ 0.2 ppm) but as 
a narrow A,B multiplet at δ = 4.66 ppm in 2. 
The presence of another pyrronazol 3 was suggested by a more lipophilic peak in the 
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This however, had the elemental formula C17H17ClN2O4 indicated by molecular ion 
clusters for [M+H]+ and [M+Na]+, and a conspicuous pyrone fragment ion [M-44 = M-
CO2]
+ in positive mode as well as [M-H]- in negative mode. The loss of one oxygen atom 
and the appearance of a new methyl group C-17 in the NMR spectra suggested the 
absence of the primary alcohol function in pyrronazole B (3) (Table D2). This small 
difference resulted in a surprising consequence in the solution conformation of 3 
compared to 1; supported by a weak ROESY correlation between H-10 and the pyrrole 
NH, the unambiguously strong correlation between methyl group C-17 and the pyrrole 
H-12 required a 180 degree turn of the pyrrole ring, positioning both in a cisoidal relation 
(Scheme D1).   
 
Table D1. NMR Data of Pyrronazol A1 (1) and A2 (2)  
    1a        2a    
Pos. δH m J [Hz] ROESY δC m H in HMBC   δH M J [Hz] ROESY δC m H in HMBC  
1       166.1  C  2          165.9  C  2  
2 5.07 s  15 88.9  CH     5.22 s  15 89.2  CH  4  
3       178.5  C  16, 4, 15, 2          178.2  C  16, 4, 15, 2  
4 2.79 qd 7.1, 3.6  5 35.8 CH  16, 2   2.99 qd 7.1, 3.7  5  36.2 CH  16, 2  
5 5.34 dd 3.6, 1.5  4 75.0 CH  16   5.64 m  4, 7  74.6  CH  16  
6       137.9  C  5, 7          137.1  C  5  
7 7.66 d 1.5   135.9  CH  5   7.85 d 1.5  5  135.5  CH  5  
8       163.6  C  17b, 17a, 10, 7         162.6  C  17, 10, 7  
9       118.3  C  17b, 17a, 10          115.1  C  17, 10  
10 7.38 s   12 126.6  CH  17b, 17a   6.79 s  17  126.1  CH  17  
11       128.0  C  13, 12, 10          127.7  C  13, 12, 10  
12 6.45 dd 3.6, 2.0  10, 13 116.9  CH  10   6.46 dd 3.6, 2.3 13  117.8  CH  13, 10  
13 6.16 dd 3.8, 1.8  12 109.1  CH     6.16 dd 3.6, 2.5 12  108.6  CH  12  
14       120.3  C            117.9  C    
15 3.75 s   56.3  CH3     3.84 s  2  56.5  CH3    
16 0.96 d 7.1  2, 4 11.4  CH3  5   1.10 d 7.3  2, 5  11.8  CH3  4, 5  
17a 4.93 d 13.2  17b 58.6  CH2  10   4.66 m  10  65.8  CH2  10  
17b 4.74 d 13.2  17a, NH                
NH 10.60 br. s  17b       13.94 br. s       
OH 4.08 br. s          n.o.        





















Table D2. NMR Data of Pyrronazol B (3) in CDCl 3  
 
No. δHa m J [Hz] ROESY δC m
b H in HMBC  
1      166.45 C  2  
2 5.16 s  15 89.11  CH    
3      178.81  C  16, 4, 15, 2  
4 2.91 qd 7.0, 3.4 5 35.93 CH  16, 2  
5 5.52 dd 3.4, 1.5 4, 7 75.44  CH  16  
6      138.23  C  5  
7 7.71 d 1.5 5 135.67  CH  5  
8      164.66  C  17, 10, 7  
9      118.47  C  17, 10  
10 7.21  m  NH 121.11  CH  17  
11      128.74  C  17, 12  
12 12  t 3.4 17 113.33  CH  10  
13 6.17  dd 3.8, 2.6 - 108.77 CH    
14      117.11  C    
15 3.80  s  2, 16, 4 56.36  CH3    
16 1.01  d 7.2  11.56  CH3 5  
17 2.34  d 1.1 12 14.79  CH3 10  
NH 8.47 s br.       
a 1H 300 and 600 MHz; b 13C 75 MHz from DEPT and HMQC 
When N. pusilla strain Na a174 was used for large-scale production of 1, a late eluting 
fraction from LH-20 chromatography of the extract showed the typical conjugated 
oxazol-pyrrole chromophore at 340-350 nm in the UV spectrum for two peaks in the 
analytical RP-HPLC-HRESIMS at 9.7 min and 11.8 min for 4 and 5, respectively. Both 
were isomers with the elemental composition C15H19ClN2O3 derived from their molecular 
ion clusters [M+H]+ at 311.1158. Their NMR spectra revealed the presence of the 
pyrrole and oxazol units like pyrronazol B (3) but lacked the 2-pyrone part of the 
molecule (Table D3). Instead, identical 2-methylbutane-1,3-diol residues were 
suggested from the COSY NMR spectra of pyrronazol C1 (4) and C2 (5). Suspicious 
shift differences of 0.7 ppm for H-10 in the 1H NMR spectra and of 6.8 ppm for C-17 in 
the 13C NMR spectra indicated different configurations of the methyl-substituted ∆9,10 
double bond. Actually, 4 was recognized as the E configured pyrronazol C isomer from 
NOESY correlations between CH3-17 and H-12 and between H-10 and the NH proton. 
Conversely, ROESY correlations were observed between CH3-17 and H-10 and 










Table D3. NMR-Data of Pyrronazol C1 (4) and C2 (5) in CDCl 3
b 
    4a        5b    
No. δH m J [Hz] NOESY δC m HMBC   δH m  J [Hz]  ROESY δC m HMBC  
2 1.27 d 6.9   21.6 CH3     1.34 d  6.4 >4 22.0 CH3  - 
3 4.33 qd 6.5, 1.7  5 >4  70.7 CH  16, 2, 5   4.38 qd  6.4, 2.3  5 >4 72.6 CH 5, 2, 16  
4 1.98 qdd 7.1, 3.2, 1.7  >3, 5  42.6 CH  16, 2   2.20 qt  7.1, 2.3  >3,5 42.3 CH 16, 2 >5  
5 4.98 dd 3.2, 0.7 4, 3 >7  72.8 CH  16, 3   5.17 dd  2.3, 1.3  3 >4 > 7 73.4 CH 3, 16 
6        143.5 C  5, 7   -      142.9 C 5, 7 
7 7.53 d 0.7    134.5 CH  5   7.62 d  1.3   134.2 CH 5  
8        164.0 C  17, 10, 7    -      163.0 C 17, 7, 10 
9        118.7 C  17, 10    -      112.2 C 17, 10  
10 7.20 br.s   NH  120.8 CH  17   6.50 br.q  1.1 12 >17 124.2 CH 17  
11        128.8 C  13, 12    -      128.6 C 10 >13 
12 6.42 br. t 3.3 17, 13  113.3 CH  10   6.28 br.dd 3.4, 2.6  10 115.1 CH 10  
13 13  dd 3.7, 2.6  12  108.7 CH  12   6.10 dd 3.6, 2.6   107.6 CH   
14        117.0 C  12    -      115.9 C   
16 0.90 d 7.1 2  5.2 CH3  3, 5   0.95 d  7.1  4.4 CH3 3, 5 >4 
17 2.34 d 0.9  12  14.8 CH3  10   2.27 d 1.1  10 21.6 CH3 10  
NH 8.29 br.s   10        14.27 br.s        
a 1H at 700.5 MHz, 13C at 176.1 MHz; b 1H at 300.1 MHz, 13C at 75.5 MHz. b The numbering scheme of pyrronazols A – B was retain d in the 
smaller C1 and C2 variants. 
A strongly preferred conformation in solution was expected from the substitution pattern 
of the 2-methylbutane-1,3-diol residue of the isomers. In the 1H NMR spectra only small 
coupling constants J3,4 and J4,5 between 1.7 and 3.2 Hz were observed for 4 and 5, 
together with a strong NOE effect between H-3 and H-5. Assuming the relative position 
of the substituents on C-4 and C-5 are similar to 1 – 3, the 4R,5S configuration was 
used to calculate the preferred conformations of the 3R and 3S isomers of pyrronazol 
C1 (4) using the conformational search module of HyperChem (Ver. 8.0). While none of 
the R,R,S conformations were compatible with the NMR restrictions, the conformation of 
the S,R,S configuration of 4 shown in Fig. D3 provided calculated coupling constants of 
2.7 and 2.3 Hz for J3,4 and J4,5, respectively. The strong NOE effects between H-3 and 
H-5 and the weaker one between H-5 and H-7 were compatible with the atom distances 
of 2.4 and 3.0 Å in the model. Additionally, the absence of any NOE effect between H-5 
and the methyl groups C-2 and C-16 was explained by the conformation of the 








Figure D3. Calculated Solution Conformation of Pyrr onazol C1 (4) 
 (HyperChem Ver. 8.0, Conformational Search (MM+), followed by optimization (pm3)) 
 
1,6-Phenazinediol (6) was isolated by Si-flash chromatography of a fraction from 
Sephadex LH-20 chromatography in dichloromethane/methanol (1:1). 6 was identified 
by HPLC-HRESI mass spectrometry and 1H and 13C NMR spectroscopy as a metabolite 










Scheme D2. 1-Hydroxy-phenazine-6-yl- α-D-arabinofuranoside (7) 
The corresponding glycoside 7 (Scheme D2) was identified by HPLC-UV-MS in a Si-
flash chromatography fraction from its similar UV spectrum and the molecular ion 
cluster [M+H]+  at m/z 345.1081 providing the elemental composition C17H17N2O6. The 
molecular ion cluster was accompanied by a typical fragment ion [M+H-C5H8O4]
+ at m/z  
213.0659 indicating the loss of a pentosyl residue. Since the carbon nuclei in furanose 
sugars are generally less shielded than in related pyranoses and the anomeric 
configuration can be differentiated by their 13C chemical shifts (Table DS6), the 
carbohydrate residue was assigned by NMR spectroscopy as an α-arabinofuranosyl 
residue (observed δC 109.1, 83.1, 78.9, 87.8, 63.1; methyl-α-furanoside δC 109.3, 81.9, 
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determined to be D-arabinose by GC-MS comparison of the (─)-2-butyl glycoside 
derivative to authentic standards (Gerwig et al., 1978). 
Pyrronazol A (1), 1,6-phenazine-diol (6) and 1-hydroxy-phenazine-6-yl-α-D-
arabinofuranoside (7) were tested for their biological activity against bacteria, fungi and 
yeasts. 1 showed weak antifungal activity against Mucor hiemalis with a minimum 
inhibitory concentration (MIC) of 33 µg/mL but no antibacterial activity, while 6 showed 
weak antibacterial and antifungal activity with a MIC of 33 µg/mL against some of the 
strains tested (Table D4). When both the compounds were assessed for cytotoxicity 
against growing cancer and primary cell lines, 1 showed no significant activity but 6 was 
active against all cell lines tested with a minimum LD50 value of 2.59 µM against SKOV3 
cells (Human ovarian carcinoma cells) (Table D5).  
 
Table D4. In-vitro Antibacterial and Antifungal Activity of Pyrronazo l A (1), 1,6-Phenazine-diol (6) and 1-Hydroxy-phena zine-
6-yl-α-D-arabinofuranoside (7) (MIC [ µg/mL]) 
Test Organism (DSM No.)  1  6 7 Control 
Chromobacterium violaceum (30191) n.i. 66.7 n.i. 2.1a 
Nocardia sp. (43069) n.i. 33.3   n.i. <0.52a 
Paenibacillus polymyxa (36) n.i. 66.7 n.i. 6.7d 
Mycobacterium sp. (43270) n.i. 66.7  2.1a 
Mycobacterium diernhoferi (43542) n.i. 33.3 66.6 <0.52a 
Mucor hiemalis (2656)                    33.3 3.3 n.i. 2.1 b 
Trichosporon oleaginosus (11815) n.i. n.i. n.i. 0.1a 
Wickerhamomyces anomalus (6766)e                 n.i. 33.3 n.i. 0.52b 
Aspergillus flavus (1959) n.i. n.i. n.i. 1.0c 
Aspergillus fumigatus (15966) n.i. n.i. 33.3 <0.52c 
a Streptomycin sulfate; b Nystatin dihydrate; n.i. no inhibition; c Amphotericin B; d Oxytetracyclin hydrochloride; e formerly Pichia anomala. 
 
Table D5. Cytotoxicity (LD 50 [µM]) of Pyrronazol A (1) and 1,6-Phenazine-diol (6) against growing cell lines. 
Cell lines Pyrronazol A (1) 1,6-Phenazine-diol (6) Ref.a 
L-929 >27.41 11.31 0.008 
KB-3-1 >27.41 5.18 0.002 
HUVEC >27.41 3.81 - 
SK-OV-3 >27.41 2.59 0.0026 
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With their tricyclic carbon skeleton the pyrronazols A (1, 2) and B (3) represent a novel 
structural class of secondary metabolites. The minor byproducts pyrronazol C1 (4) and 
C2 (5) observed with N. pusilla strain Na a174 are probably degradation products, 
which are sometimes observed to a greater extent after a prolonged cultivation period. 
As next related natural products (Scheme D3) pyoluteorin (Takeda, 1958), a pyrrole 
antibiotic from Pseudomonas aeruginosa and P. fluorescens with antibacterial, 
antifungal and herbicidal properties might be seen, or pyrrolomycin B (Kaneda et al., 
1981) from Actinosporangium vitaminophilum with antibiotic, antifungal and immune-
potentiator properties as well as the phorbazole D variants (Rudi et al., 1994), 
immunomodulators from the marine sponge Phorbas aff. clathrata. Another antifungal 
pyrrole antibiotic, the 3-chloro derivative pyrrolnitrin was isolated among others from the 
myxobacterium Myxococcus fulvus (Gerth et al., 1982). 
 
 
Scheme D3. Pyrrole antibiotics 
1,6-Phenazine-diol (6) belongs to a phenazine family of compounds and has been 
reported previously from of diverse microorganisms such as Brevibacterium iodinum, 
Microbispora aerata, Streptomyces thioluteus, Pseudomonas iodine and Nocardiopsis 
dassonvillei(Gerber and Lechevalier, 1965; Podojil and Gerber, 1967; Tsujibo, 1988). 
The glycosyl derivative, 1-hydroxy-phenazine-6-yl-α-D-arabinofuranoside (7) was 
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D.4. Experimental Section  
D.4.1. General Experimental Procedures.  Melting points were measured on a Büchi-
510 melting point apparatus; UV data were recorded on a Shimadzu UV/Vis-2450 
spectrophotometer in methanol (UVASOL, Merck); IR data were recorded on a Bruker 
Tensor 27 IR spectrophotometer. 1H NMR and 13C NMR spectra were recorded on 
Bruker Avance DMX 600 or DPX 300 NMR spectrometers, locked to the deuterium 
signal of the solvent. Data acquisition, processing and spectral analysis were performed 
with standard Bruker software and ACD/NMR Spectrus. Chemical shifts are given in 
parts per million (ppm) and coupling constants in Hertz (Hz). HRESIMS data were 
recorded on a Maxis ESI TOF mass spectrometer (Bruker Daltonics), molecular 
formulae were calculated including the isotopic pattern (Smart Formula algorithm). 
Analytical RP HPLC was carried out with an Agilent 1260 HPLC system equipped with a 
diode-array UV detector (DAD) and a Corona Ultra detector (Dionex) or a Maxis ESI 
TOF mass spectrometer (Bruker Daltonics). HPLC conditions: Waters Acquity C18 
column 50×2 mm, 1.7 µm, solvent A: H2O, 0.1% HCOOH; solvent B: acetonitrile, 0.1% 
HCOOH; gradient system: 5% B for 1 min, increasing to 95% B in 20 min; flow rate 0.6 
mL/min; 40 oC. 
The myxobacterial strain Nannocystis pusilla, strain Ari7 was isolated in 1980 from a 
soil sample collected on Langeoog island, Germany, in 1977 and strain Na a174 was 
isolated from soil with plant residues from Rhodos island, Greece in 1999. 
D.4.2. Isolation of Pyrronazols A, A2 and B from N. pusilla, strain Ari 7 
Fermentation.  The strain was stored at -80 °C. It was reactivate d in 20 mL of liquid 
media consisting of 0.3% probion (single cell protein, Hoechst), 0.3% starch (Cerestar), 
0.2% MgSO4 × 7 H2O, 0.05% CaCl2 × 2 H2O, 50 mM HEPES at pH 7.2. 20 µL of vitamin 
solution was added to the culture. The culture was scaled up to 1L and used as 
inoculum for a fermentation of strain Ari7 that was performed in the same media as 
above but supplemented with 2% Amberlite XAD-16 resin in a 10 L bioreactor. The 
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agitated with a flat blade turbine stirrer at 100 rpm for 7 days. At the end of fermentation 
the XAD resin (181 g) was collected from the culture by sieving. 
Extraction and Isolation. The XAD adsorber resin was stored overnight in methanol 
and extracted three times in a glass column with 3 bed volumes of methanol. The 
methanol extract was evaporated to an aqueous mixture, diluted with water and 
extracted with ethyl acetate (three times with 150 mL).The combined ethyl acetate was 
dried with Na2SO4. It was evaporated to give 1.34 g of crude extract. A further solvent-
solvent partitioning was done between methanol and n-heptane to eliminate lipophilic 
compounds. Methanol–n-heptane (100 mL) partitioning was repeated twice to give 914 
mg of an enriched crude methanol extract. This crude extract was further separated by 
Sephadex LH-20 chromatography [column 4×84 cm; solvent dichloromethane - 
methanol (1:1); flow rate 3.6 mL/min, UV detection at 275nm] to obtain two fractions 
with crude 1,6-phenazinediol (4) (62 mg) and a fraction 2 (325 mg) after evaporation of 
the organic solvent.  
Crude 4 was dissolved in methanol (50 mL) and evaporated with silica gel (11 g). The 
dried silica gel was used in a solid loader for further purification by silica gel flash 
chromatography (Reveleris Flash Chromatography System; column 12 g silica 40 µ), 
solvent dichloromethane for 10 min; flow rate 36 mL/min; UV detection at 350 nm and 
270 nm) yielding pure 1,6-phenazinediol (4) (17 mg).  
The fraction 2 was dissolved in methanol and purified subsequently by RP-MPLC 
chromatography [column 480×30 mm (Kronlab), ODS-AQ C18 (YMC), S 16 µm; solvent 
A: H2O-methanol 1/1; solvent B: methanol; gradient: 15% B to 40% B in 120 min; flow 
rate 30 mL/min; UV detection at 350 nm] to give four fractions; fraction 2 (58 mg), 
fraction 3 (13 mg), fraction 4 containing pure pyrronazol A2 (2) (3.5 mg), and fraction 5 
with pure pyrronazol B (3) (2 mg). Fraction 2 was dissolved in DMSO and ultimately 
purified by two preparative RP-HPLC runs [column 250×21 mm, Nucleodur 100-10 C18 
EC, S 10 µm; solvent A: H2O-methanol 1/1; solvent B: methanol; gradient: 15% B to 
30% B in 60 min; flow rate 20 mL/min; UV detection at 350 nm] yielding pure pyrronazol 
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Fraction 3 was purified by preparative TLC [20 × 20 cm, 0.25 mm, silica gel 60 F254 nm 
(Merck), dichloromethane-MeOH (9:1), UV detection at 254 nm]. The UV active zone 
was eluted and to yield 3.2 mg of 1-Hydroxy-phenazine-6-yl-α-D-arabinofuranoside (7). 
D.4.3. Isolation of Pyrronazol C1 and C2 from N. pusilla, strain Na a174 
Fermentation.  Strain Naa174 was cultivated in 65 L of a medium consisting of 1 % 
probion (single cell protein, Hoechst), 0.1% MgSO4 × 7 H2O, 0.05% CaCl2 × 2 H2O, and 
50 mM HEPES in the presence of 1 % Amberlite XAD-16 in a 100 L bioreactor. The 
bioreactor was kept at 30 °C, aerated at 0.05 vvm p er minute, pH regulated at 7.2, and 
agitated with a flat blade turbine stirrer at 110 rpm for 4 days. At the end of fermentation 
the XAD resin and cells (1.6 kg) were collected from the culture by sieving. 
Isolation.  Amberlite XAD 16 from a fermentation of strain Naa174 was extracted with 
acetone (three times, 6 L each) under stirring and filtered through filter paper on a 
Buchner funnel. The combined extracts were evaporated providing aqueous oil, which 
was extracted with dichloromethane. After evaporation 22.5 g of a raw extract remained, 
that was partitioned between methanol and heptane (1:1, 3 times). After evaporation of 
the methanol, 8.1 g of a raw product was obtained and separated by LH-20 column 
chromatography (column 70×600 mm, dichloromethane-methanol 8:2, flow rate 10 
mL/min; 3 runs). Five fractions were collected guided by TLC and UV absorption (365 
nm). Fraction 2 contained pyrronazol A1 (1) (3.1 g with about 0.5 g of 1). Fraction 5 (82 
mg) was separated by RP-HPLC [column 22×250 mm, RP-18, solvent gradient 50 to 
100% MeOH in 30 min, flow 23 mL/Min; UV detection 350 nm) to give fraction 5.1 (5.6 
mg) containing enriched pyrronazol C1 (4) and fraction 5.3 (3.4 mg) containing enriched 
pyrronazol C2 (5). Both fractions were again purified by RP-HPLC. 
D.4.4. X-Ray Structure Determination of Pyrronazol A (1) 
Crystals suitable for single-crystal x-ray analysis were obtained from methanol. 
Although chlorine is not sufficient normally, fortunately in this case the crystal was of 
real good quality and allowed the determination of the absolute configuration from 
structure refinement. The data were collected at 132 K on a BrukerAXS X8Apex CCD 
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0.5° oscillation were exposed; deriving data in the  θ range of 2 to 33° with a 
completeness of ~95%. Structure solution and full least-squares refinement with 
anisotropic thermal parameters of all non-hydrogen atoms and free refinement of the 
hydrogen were performed using SHELX (Sheldrick, 2008). The final refinement resulted 
in: R1= 0.039, wR2= 0.087, S = 1.009 and Flack = 0.00(4) for the correct structure and 
R1 = 0.041, wR2= 0.093, S= 1.075 and Flack = 0.99(6) for the opposite configuration. 
D.4.5. Structural characteristics of compounds isol ated  
Pyrronazol A1  (1) 6-{2-[(1E)-1-(5-chloro-1H-pyrrol-2-yl)prop-1-en-2-yl]-1,3-oxazol-4-yl}-
4-methoxy-5-methyl-5,6-dihydro-2H-pyran-2-one: C17H17ClN2O5 M = 364.78; HPLC 
System A: Rt 10.2 min; mp.  150 °C decomp.; [ α]
22
D  – 134.4 (c = 8 mg/cm
-3, CH3OH); 
UV (MeOH): λmax (log ε) 232 (4.229), 346 (4.484) nm; IR (KBr) νmax 1681 (s), 1617 (s), 
1223 (s), 781 (m) cm-1; NMR data, see Table D1; HRESIMS m/z 365.0903 [M+H]+ 
(calcd. for C17H18ClN2O5, 365.0899), m/z  387.0726 [M+Na]
+ (calcd. for 
C17H17ClN2O5Na, 387.0718), m/z 347.0798 [M-H2O+H]
+ (calcd. for C17H16ClN2O4, 
437.0793), m/z 363.0751 [M-H]- (calcd. for C17H16ClN2O5, 363.0753). 
Pyrronazol A2 (2) 6-{2-[(1Z)-1-(5-chloro-1H-pyrrol-2-yl)-3-hydroxyprop-1-en-2-yl]-1,3-
oxazol-4-yl}-4-methoxy-5-methyl-5,6-dihydro-2H-pyran-2-one): C17H17ClN2O5 M = 
364.78; [α]22D – 366 (c = 0.0038 g/cm
-3, CH3OH); UV (MeOH): λmax (log ε) 233 (4.313), 
353 (4.266) nm; NMR data, see Table D1; HRESIMS m/z 365.0900 [M+H]+ (calcd. for 
C17H18ClN2O5, 365.0899), m/z 347.0793 [M-H2O+H]
+ (calcd. for C17H16ClN2O4, 
437.0793).  
Pyrronazol B  (3) (5R,6R)-6-{2-[(1E)-1-(5-chloro-1H-pyrrol-2-yl)prop-1-en-2-yl]-1,3-
oxazol-4-yl}-4-methoxy-5-methyl-5,6-dihydro-2H-pyran-2-one: C17H17ClN2O4 M = 
348.78; HPLC System A: Rt 11.8 min; m.p. 215-6 °C; [ α]
22
D  – 132.3 (c = 5.3 mg/cm
-3, 
CH3OH); UV (MeOH): λmax (log ε) 231 (3.852), 338 (4.038) nm; IR (KBr) νmax 1704 (s), 
1629 (s), 1618 (s), 1379 (s) 1222 (s), 765 (m) cm-1; NMR data, see Table D2; HRESIMS 
m/z 349.0954 [M+H]+ (calcd. for C17H18ClN2O4, 349.0950), m/z 305.1057 [M+H-CO2]
+ 
(calcd. for C16H18ClN2O2, 305.1051), m/z 371.0756 [M+Na]
+ (calcd. for C17H17ClN2O4Na, 
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Pyrronazol C1  (4) 1-{2-[(1E)-1-(5-chloro-1H-pyrrol-2-yl)prop-1-en-2-yl]-1,3-oxazol-4-yl}-
2-methylbutane-1,3-diol: C15H19ClN2O3 M = 310.78; HPLC System A: Rt 9.7 min;  α
22
D 
UV (MeOH): λmax (log ε) 341 (3.381) nm; NMR data, see Table D3; HRESIMS m/z 
311.1167 [M+H]+ (calcd. for C15H20ClN2O3, 311.1157). 
Pyrronazol C2  (5) 1-{2-[(1Z)-1-(5-chloro-1H-pyrrol-2-yl)prop-1-en-2-yl]-1,3-oxazol-4-yl}-
2-methylbutane-1,3-diol: C15H19ClN2O3 M = 310.78;  HPLC System A: Rt 11.85 min;   
α
22
D UV (MeOH): λmax (log ε) 349 (3.851) nm; NMR data, see Table D3; HRESIMS m/z 
311.1158 [M+H]+ (calcd. for C15H20ClN2O3, 311.1157). 
1,6-Phenazine-diol  (6): HPLC System A: Rt 7.3 min, UV λmax 271, 373, 442 nm;   
1H 
NMR (400 MHz, DMSO-d6) δ 10.48 (2H, br. s., OH), 7.76 (2H, dd, J = 8.6 Hz, J = 7.1 
Hz, CH), 7.72 (2H, dd, J = 8.6 Hz, J = 1.5 Hz, CH), 7.19 (2H, dd, J = 6.9 Hz, J = 1.8 Hz, 
CH); 13C NMR (101 MHz, DMSO-d6) δ 110.52 (CH), 119.12 (CH), 131.27 (CH), 135.66, 
142.06, 153.37; HRESIMS m/z 213.0662 [M+H]+ (calcd. for C12H8N2O2, 213.0659). 
1-Hydroxy-phenazine-6-yl- α-D-arabinofuranoside  (7): C17H16N2O6 M = 344.32;  
HPLC System A: Rt 5.47 min; UV (MeOH): λmax (log ε) 270 (4.698), 371 (3.496), 436 
(3.232) nm; NMR data, see Table DS6; HRESIMS m/z 345.1081 [M+H]+ (calcd. for 
C17H17N2O6, 345.1081), m/z  213.0659 [M+H-C5H8O4]
+ (calcd. for C12H9N2O2, 
213.0659). 
D.4.6. Antimicrobial Testing 
20 µl aliquots (conc. 1 mg/mL) of compound 1, 6, 7 and reference drugs (streptomycin 
against bacteria and nystatin against yeast and fungi) were tested against 5 bacteria 
(Chromobacterium violaceum, Nocardia sp., Paenibacillus polymyxa, Mycobacterium 
sp., Mycobacterium diernhoferi), fungi (Mucor hiemalis, Aspergillus fumigatus), and two 
yeasts (Pichia anomala (recently the name P. a. was changed to Wickerhamomyces 
anomalus). The MIC values were determined in 96 well microtitre plates by 1:1 serial 
dilution in EBS medium (0.5 % casein peptone, 0.5 % protease peptone, 0.1 % meat 
extract, 0.1 % yeast extract, pH 7.0) for bacteria and MYC medium (1.0 % glucose, 1.0 
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previously described (Okanya et al., 2011). The test organisms were cultivated at 30 °C 
and 160 rpm for 24-48 hrs and the cell concentration adjusted to OD600 0.01 for bacteria 
and OD548 0.1 for yeasts before the test. The lowest concentration of the drug 
preventing visible growth of the test organism was taken as the MIC.  
D.4.7. Cytotoxicity assay  
In-vitro cytotoxicity (IC50) was determined for compound 1 and 6 against a number of 
mammalian cell lines including the mouse fibroblast cell line L929, the cervix carcinoma 
cell line KB-3-1, non-transformed human umbilical vein endothelial cell line HUVEC, 
human ovarian carcinoma cell line SKOV3, adenocarcinomic human alveolar basal 
epithelial cell A549. KB-3-1, A549 and L929 were cultured in DMEM (Lonza), HUVEC 
was cultured in EBM-2 (Lonza) and SKOV3 was cultured in McCoy´s (Lonza) media, all 
supplemented with 10% of fetal bovine serum (Gibco) and incubated under 10% CO2 at 
37 °C. The MTT (2-(4,5-dimethylthiazol-2-yl)-2,5-di phenyltetrazolium bromide) method 
was used for the cytotoxicity assay on 96 well microplates as described previously. 
Methanol was used as negative control. 
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Table DS1.  Crystal data and structure refinement for Pyrr onazol A1 (1
Identification code sh3288






Unit cell dimensions a = 7.6925(7) Å
b = 10.9091(8) Å
c = 10.2880(8) Å
Volume 863.34(12) Å
Z 2 
Density (calculated) 1.403 Mg/m
Absorption coefficient 0.252 mm
F(000) 380
Crystal size 1.13 x 0.84 x 0.32 mm
Theta range for data collection 1.98 to 32.92°
Index ranges -11<=h<=6, 
Reflections collected 9117
Independent reflections 5584 [R(int) = 0.0203]
Completeness to theta = 32.92° 92.9 %
Absorption correction Semi
Max. and min. transmission 0.9229 and 0.7649
Refinement method Full
Data / restraints / parameters 5584 / 66 / 294
Goodness-of-fit on F2 1.009
Final R indices [I>2sigma(I)] R1 = 0.0346, wR2 = 0.0841
R indices (all data) R1 = 0.0393, wR2 = 0.0875
Absolute structure parameter 0.00(4)
Largest diff. peak and hole 0.438 and 
                    Pyrronazols from 
 
 









      α= 90° 
    β= 90.238(5)° 











-empirical from equivalents 
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Table DS2.  Atomic Coordinates (×10 4) and Equivalent  Isotropic Displacement Parameters  (Å2× 103) for Pyrronazol A1 (1). 
U(eq) is defined as one third of  the trace of the orthogonalized U ij  tensor . 
 x y z U(eq) 
 
Cl(1) -294(1) 5373(1) 1719(1) 24(1) 
O(1) 13021(1) 7434(1) 6425(1) 17(1) 
O(2) 15685(1) 7783(1) 7123(1) 23(1) 
O(3) 12371(2) 4636(1) 9087(1) 22(1) 
O(4) 8339(1) 8248(1) 4529(1) 17(1) 
O(5) 4504(1) 4925(1) 4266(1) 18(1) 
N(1) 8965(2) 6303(1) 4989(1) 15(1) 
N(2) 2599(2) 6376(1) 2658(1) 16(1) 
C(1) 14397(2) 7130(1) 7177(1) 18(1) 
C(2) 14250(2) 6084(1) 8048(1) 19(1) 
C(3) 12714(2) 5527(1) 8227(1) 16(1) 
C(4) 11130(2) 5904(1) 7474(1) 17(1) 
C(5) 11739(2) 6482(1) 6195(1) 14(1) 
C(6) 10280(2) 7050(1) 5456(1) 14(1) 
C(7) 9911(2) 8233(1) 5181(1) 17(1) 
C(8) 7854(2) 7053(1) 4451(1) 14(1) 
C(9) 6227(2) 6737(1) 3814(1) 14(1) 
C(10) 5098(2) 7626(1) 3450(1) 16(1) 
C(11) 3436(2) 7484(1) 2820(1) 16(1) 
C(12) 2389(2) 8376(1) 2261(2) 22(1) 
C(13) 895(2) 7800(1) 1747(2) 22(1) 
C(14) 1075(2) 6578(1) 2035(1) 18(1) 
C(15) 5969(2) 5387(1) 3556(1) 16(1) 
C(16) 9968(2) 6739(2) 8293(1) 26(1) 
C(17)                      13732(2)               4272(2)                9966(2)                     28(1) 
Table DS3. Bond lengths [Å] and angles [°] for Pyrr onazol A1 (1) 
Cl(1)-C(14)  1.7149(14) 
O(1)-C(1)  1.3496(15) 
O(1)-C(5)  1.4516(15) 
O(2)-C(1)  1.2218(17) 
O(3)-C(3)  1.3415(16) 
O(3)-C(17)  1.4357(18) 
O(4)-C(8)  1.3592(15) 
O(4)-C(7)  1.3805(17) 
O(5)-C(15)  1.4363(17) 
O(5)-H(11)  0.79(3) 
N(1)-C(8)  1.3044(16) 
N(1)-C(6)  1.3840(16) 
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N(2)-C(11)  1.3796(17) 
N(2)-H(8)  0.92(2) 
C(1)-C(2)  1.4554(19) 
C(2)-C(3)  1.3425(19) 
C(2)-H(1)  0.945(19) 
C(3)-C(4)  1.4991(18) 
C(4)-C(16)  1.531(2) 
C(4)-C(5)  1.5338(18) 
C(4)-H(2)  0.99(2) 
C(5)-C(6)  1.4891(17) 
C(5)-H(3)  0.928(18) 
C(6)-C(7)  1.3501(17) 
C(7)-H(4)  0.95(2) 
C(8)-C(9)  1.4519(18) 
C(9)-C(10)  1.3535(18) 
C(9)-C(15)  1.5094(18) 
C(10)-C(11)  1.4396(18) 
C(10)-H(5)  0.94(2) 
C(11)-C(12)  1.3858(19) 
C(12)-C(13)  1.410(2) 
C(12)-H(6)  0.95(2) 
C(13)-C(14)  1.373(2) 
C(13)-H(7)  1.01(2) 
C(15)-H(9)  0.983(16) 
C(15)-H(10)  0.981(19) 
C(16)-H(12)  1.00(2) 
C(16)-H(13)  0.90(3) 
C(16)-H(14)  0.97(2) 
C(17)-H(15)  0.92(2) 
C(17)-H(16)  0.86(2) 
























































































Table DS4. Anisotropic displacement parameters (Å 2×103) for Pyrronazol A1 (1).  The anisotropic displacem ent factor 
exponent takes the form:  -2 π2[ h2 a*2U11 + ...  + 2 h k a* b* U 12  
 U11 U22  U33 U23 U13 U12 
Cl(1) 19(1)  27(1) 25(1)  -3(1) -1(1)  -7(1) 
O(1) 15(1)  13(1) 24(1)  3(1) -5(1)  -2(1) 
O(2) 18(1)  18(1) 34(1)  4(1) -6(1)  -4(1) 
O(3) 24(1)  20(1) 24(1)  9(1) -5(1)  -1(1) 
O(4) 16(1)  11(1) 24(1)  1(1) -5(1)  -1(1) 
O(5) 19(1)  11(1) 26(1)  1(1) 2(1)  -1(1) 
N(1) 14(1)  11(1) 18(1)  -1(1) -3(1)  0(1) 
N(2) 14(1)  15(1) 21(1)  0(1) -2(1)  0(1) 
C(1) 16(1)  14(1) 22(1)  0(1) -5(1)  1(1) 
C(2) 18(1)  16(1) 22(1)  2(1) -6(1)  0(1) 
C(3) 20(1)  12(1) 18(1)  1(1) -4(1)  1(1) 
C(4) 17(1)  15(1) 18(1)  2(1) -4(1)  -1(1) 
C(5) 14(1)  11(1) 18(1)  0(1) -2(1)  -1(1) 
C(6) 14(1)  12(1) 16(1)  -1(1) -1(1)  0(1) 
C(7) 15(1)  12(1) 23(1)  1(1) -4(1)  -1(1) 
C(8) 14(1)  9(1) 18(1)  -1(1) 0(1)  0(1) 
C(9) 13(1)  12(1) 18(1)  -1(1) -2(1)  0(1) 
C(10) 16(1)  13(1) 21(1)  0(1) -2(1)  1(1) 
C(11) 15(1)  13(1) 20(1)  -1(1) -2(1)  0(1) 
C(12) 18(1)  17(1) 30(1)  2(1) -4(1)  3(1) 
C(13) 16(1)  23(1) 26(1)  2(1) -6(1)  4(1) 
C(14) 14(1)  21(1) 18(1)  -1(1) -2(1)  -1(1) 
C(15) 13(1)  12(1) 23(1)  -2(1) 0(1)  0(1) 
C(16) 25(1)  33(1) 20(1)  3(1) 3(1)  9(1) 
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Table DS5. Hydrogen coordinates (×10 4) and isotropic displacement parameters (Å 2×10 3) for Pyrronazol A1 (1)  
 x  y  z  U(eq) 
H(1) 15230(30) 5902(18) 8573(18) 23(5) 
H(2) 10530(30) 5140(20) 7199(18) 27(5) 
H(3) 12260(30) 5884(16) 5685(16) 16(4) 
H(4) 10420(30) 9020(20) 5261(18) 23(5) 
H(5) 5420(30) 8441(19) 3637(18) 19(4) 
H(6) 2660(30) 9230(20) 2220(20) 33(5) 
H(7) -90(30) 8130(19) 1200(20) 27(5) 
H(8) 2900(30) 5680(20) 3110(20) 36(6) 
H(9) 5780(20) 5275(18) 2617(16) 16(4) 
H(10) 7020(30) 4944(17) 3825(17) 19(4) 
H(11) 4360(30) 4240(20) 4030(30) 47(7) 
H(12) 8860(30) 6930(20) 7830(20) 38(6) 
H(13) 10510(40) 7450(30) 8450(20) 52(8) 
H(14) 9740(30) 6330(20) 9120(20) 35(5) 
H(15) 14650(30) 3912(19) 9548(17) 21(5) 
H(16) 13250(30) 3780(18) 10506(18) 18(4) 































































































































































Figure DS6. HMBC- (green) and ROESY (violet) correl ations of 1,6-Phenazine-diol- α-D-arabinofuranoside (7) 
 
Table DS6. NMR Data of 1,6-Phenazine-diol- α-D-arabinofuranoside (7) in CD 3OD [
1H 600 MHz; 13C 100 MHz] 
Pos. δH H  J [Hz] ROESY  δC m  H in HMBC  
1         154.73  C  2, 3  
10a         137.45  C  2  
2  7.22 br. d 6.2   111.69  CH    
3  7.80 m   4  133.51  CH    
4  7.78 m   3  120.10  CH  2  
4a         144.14  C  3  
5a         138.48  C  7  
6         152.94  C  1’, 7, 8  
7  7.57 br. d 7.3 1’  115.07  CH  9  
8  7.82 m    131.60  CH    
9  8.01 br. d 7.7   124.10  CH  7  
9a         143.91  C  8  
1'  5.95 br. s  3’, 2’, 7  109.09  CH    
2'  4.65 dd 3.3, 1.1 3’, 4’, 1’  83.09  CH  3’  
3'  4.08 dd 5.5, 3.3 5'ab, 4’, 1’, 2’  78.90 CH  5'ab, 4’, 2’, 1’  
4'  4.18 td 5.2, 3.5 3’, 2’  87.84  CH  5'b, 1’  
5'a 3.78  dd 12.1, 3.3 5'b, 3’    3’  

































































































Figure DS7. 1H NMR spectrum of Pyrronazol A (1) in CDCl 3 (400 MHz) 
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Figure DS11. 1H NMR spectrum of Pyrronazol B (3) in CDCl 3 (400 MHz) 
MICF9829.100.001.1r.esp





























































































































































































Figure DS13. 1H NMR spectrum of Pyrronazol C2 (5) in CDCl 3 (300 MHz) (Broad singlet at 14.27 ppm not shown) 
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Figure DS16. 13C NMR spectrum of 1,6-Phenazine-diol- α-D-arabinofuranoside (7) in CD 3OD (100.65 MHz) 
 







It is evident that microbes are accountable for plethora of human and animal ailments 
but the fact that most drugs currently in clinical application have been derived from 
microorganisms is also undeniable (Newman and Cragg, 2012). While fungi and 
actinobacteria have long established themselves as two of the most renowned 
sources of microbial drugs, other groups like Bacillus, cyanobacteria and 
myxobacteria are slowly emerging as the future potential sources for microbial drugs 
(Berdy, 2012). New technologies based on genome mining, high throughput 
screening and modern purification methods complement the age old culture based 
methods of drug discovery and aid to explore the metabolic diversity of the microbial 
world. This study mainly focused on discovery of novel microbial natural products and 
myxobacterial taxons and the outcome and future prospects of the study are 
discussed in this chapter.  
E.1. Paenilarvins, antifungal peptides from honey bee pathogen, 
Paenibacillus larvae 
Paenibacillus larvae has been the subject of studies since many decades to unravel 
the virulence factors and the strategies it employs during infection of the host i.e. 
honey bee larvae. The partial genome sequences available and the proteomics 
studies have helped to determine some important virulence factors and their role in 
pathogenesis including toxins, proteases, and S-layer protein (Fünfhaus et al., 2009; 
Antunez et al., 2010). It is also evident from the results that both prominent 
genotypes of P. larvae, ERIC I and II adapt different approaches for infection 
(Poppinga et al., 2012; Fünfhaus et al., 2013).    
Complete genome sequencing and annotation of P. larvae ERIC I and II in the group 
of Prof. Rolf Daniel, University of Göttingen, brought into light an astounding arsenal 
of virulence factors that could possibly allow the pathogen to conquer various sites in 
the host throughout the course of infection (Djukic et al., unpublished). One of the 





Fig.E1. Antifungal activity of crude methanol 
extract of P. larvae ERIC II (DSM 25430) against 
Mucor hiemalis after HPLC fractionation 
most interesting sequences confirmed from this study with respect to pathogenicity 
were the NRPS and NRPS/PKS hybrid biosynthetic gene clusters which putatively 
coded for some secondary metabolites (Fünfhaus et al., 2009).   
With the aim of finding the bioactive products of these biosynthetic gene clusters, 
methanol extracts from P. larvae ERIC I and 
ERIC II were screened for antimicrobial activity 
and exhibited antifungal activity. Bioactivity 
guided HPLC and LC-MS data analysis of P. 
larvae ERIC II extracts indicated production of 
a group of lipopeptides with masses ranging 
from 1069 to 1112 Da. Characterization of the 
pure compounds   based on molecular 
formulae and UV spectra revealed their affiliation to iturin family compounds including 
iturins, mycosubtilin and bacillomycin which are known to be produced by most 
Bacillus species (Ongena and Jacques, 2008). This family of compounds along with 
other Bacillus lipopeptides plays an important role in control of fungal 
phytopathogens in their natural environments (Romero et al., 2007) establishing their 
producers as versatile biocontrol agents (Zeriouh et al., 2011).  
The complete structure elucidation of some of the lipopeptides produced by P. larvae 
using NMR spectroscopy and MS-MS fragmentation firmly established the 
resemblance of these lipopeptides to Mojavensin A, produced by Bacillus mojavensis 
B0621A (Ma et al., 2012) except the length of the β-Aa side chain in one of the 
compounds and replacement of asparagine by aspartic acid in another. All the other 
compounds obtained were found to be derivatives of these two major classes with 
the difference in the length of the β-Aa side chain.  
These lipopeptides were named paenilarvins and the major products were 
paenilarvins A-C. The antifungal activity observed for paenilarvins against certain 
fungi was significantly higher than reported for Anteiso-C15 mojavensin A (1) against 
some soil-borne phytopathogens like Valsa mali, Fusarium oxysporum f. sp. 
cucumerinum, and Fusarium verticillioides (Ma et al., 2012). However, P. larvae can 
never be utilized for phytopathogen control because of its lethal effects on Apis 
mellifera whereas in fact the simultaneous production of many lipopeptides like 





surfactins, fengycins and iturins, with good biological activity by the marine- derived 
bacterium Bacillus mojavensis B0621A makes it a potential biocontrol agent (Ma et 
al., 2012).  
Paenilarvins exhibited no antibacterial activity but some cytotoxic activity against 
mouse fibroblast cell line L929. Further experiments using different concentrations of 
compounds on honey bee larvae can help to determine their larval toxicity. 
Paenilarvins could be directly insecticidal to the bee larvae like bassianolide, an 
insecticidal cyclodepsipeptide produced by the fungus, Beauveria bassiana and 
Verticillium lecanii (currently known as Lecanicillium lecanii), which elicits atonic 
symptoms in silkworm larvae (Kanoaka et al., 1977) or they could indirectly assist in 
disease progression. 
Production of secondary metabolites with antibiotic activity by a pathogen is very 
common in order to eliminate other potential pathogens of the same host (Axelrood et 
al., 1988). Many infectious agents like parasites, mites, fungi and viruses apart from 
P. larvae pose a serious threat to honey bee larvae (Murray and Aronstein, 2008; 
Puerta et al., 1999) and production of paenilarvins could help the producer to 
establish its dominance over other pathogens. They might also give a growth 
advantage to the pathogen in the competitive environment of larval gut microflora.  
It has been proven that antibiotics can act at much lower concentrations than their 
lethal dose in natural environments and target and regulate different genes including 
virulence genes (Aminov, 2009).  A polypeptide encoded by a NRPS in the citrus 
pathogen Alternaria alternata, can regulate siderophore and melanin production, iron 
uptake under low iron conditions, oxidative stress resistance, conidia formation and 
virulence (Chen et al., 2013).  
Thus, it can be speculated that paenilarvins aid the pathogen during infection using 
any of the above mentioned or any other mechanism but their exact role in disease 
progression still needs to be thoroughly investigated. Construction of P. larvae 
mutants lacking expression of NRPS/PKS gene cluster responsible for paenilarvin 
production can help to ascertain their role as virulence factors. An insight into the 
biosynthesis of paenilarvins in P. larvae and their precise molecular mechanism of 
action inside the bee larvae is also essential. Another main objective for future should 





be identification, purification and characterization of the products of other NRPS/PKS 
gene clusters in the P. larvae genome and to establish their role in pathogenesis.  
E.2. Aggregicoccus edoensis gen. nov., sp. nov., a soil 
myxobacterium with characteristic aggregation  
Myxococcaceae include four genera of myxobacteria, namely, Myxococcus, 
Corallococcus, Pyxidicoccus and Anaeromyxobacter. No new genus has been added 
to the family since the description of facultative anaerobic Anaeromyxobacter 
dehalogenans in 2002 (Sanford et al., 2002). Hereby we describe a novel genus in 
the Myxococcaceae, Aggregicoccus represented by two strains of the novel species 
A. edoensis, MCy1366T (Ar1733T) and MCy10622 (SBCy015) which were isolated 
from soil samples from different locations (Japan, Switzerland resp.) and at different 
times (1980, 2013 resp.) at HZI in our continuing efforts to isolate new myxobacteria.  
The 16S rRNA gene sequence of strain MCy1366T was analyzed together with other 
50 myxobacterial strains selected from our in house myxobacterial strain collection. It 
exhibited only 97.56% 16S rRNA gene sequence similarity to Stigmatella koreensis 
strain KYC-1019 (no valid description available, accession no. EF112185) in BLAST 
N analysis and branched out notably from all other known genera of myxobacteria in 
the phylogenetic tree. Hence, it was chosen for further study as a novel taxon.  
Strain MCy10622 was isolated by Ram Awal Prasad, Helmholtz Institute for 
Pharmaceutical Research, Saarbrücken and characterized as strain belonging to 
Myxococcaceae. It was upon comparison of the 16S rRNA gene sequence of 
MCy1366T with MCy1366T that they were found to be 99.9% similar and hence, 
representing the same taxon. The morphological characteristics like swarming 
pattern and shape and size of fruiting body like structures, vegetative cells and 
myxospore like structures indicated that the two strains belong to the family 
Myxococcaceae.  
A polyphasic approach including genotypic, phenotypic and chemotypic features was 
followed to investigate the reliable taxonomic status of MCy1366T and MCy10622 
because of their close relation to Corallococcus species (97%) on the basis of 16S 
rRNA gene sequences and similar G+C content (65.6%). The 3% sequence 





divergence suggested the two novel strains to represent a new species but in depth 
analysis was needed to confirm the results.  
The two isolates under study were checked for their physiological characteristics like 
antibiotic resistance, carbon and nitrogen source requirements, optimum temperature 
and pH for growth, starch, chitin and cellulose degradation, Congo Red reaction, salt 
tolerance, microbial predation and APIZym assay for enzyme production. Most of the 
results from the physiological studies like positive Congo Red reaction, inability to 
degrade monosaccharides, disaccharides, chitin and cellulose definitely placed them 
in the family Myxococcaceae but could not provide any clear delineation from the 
already known genera in the family.   
Fatty acid content including FA types, FA ratio and major FA markers have been 
successfully used to determine the chemo-phylogenetic relationship within the order 
Myxococcales (Garcia et al., 2011). Around 34 FAs have been reported in members 
of the family Myxococcaceae (Garcia et al., 2011), but only 26 could be detected in 
MCy1366T and 27 in MCy10622, some of which were present in very minute 
quantities. The close divergence of MCy1366T and MCy10622 from Corallococcus 
exiguus and C. coralloides was reflected in their SCFAs to BCFAs ratio. An extensive 
analytical study of FA profiles of MCy1366T and MCy10622 along with other closely 
related strains in comparison to the FA profiles of other myxobacteria already 
illustrated in literature supported the taxonomic placement of the new isolate into a 
new taxon.  
DNA-DNA hybridization is based on comparison between whole genomes of two 
bacterial strains and has been applied as one of the most important tools for bacterial 
systematics since almost 50 years (Goris et al., 2007). A group of bacteria showing 
70% or more DNA-DNA relatedness is often regarded as belonging to same species 
(Prakash et al., 2007). So, DNA-DNA hybridization was employed to ascertain the 
status of MCy1366T and MCy10622 as a new genus or a new species. 28-35% DNA-
DNA relatedness of MCy1366T with Corallococcus spp. and 100% DNA-DNA 
relatedness of MCy1366T with MCy10622 clearly advocated their description as two 
isolates of one species in a new genus. 





Matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) mass 
spectrometric analysis has become an important tool in chemotaxonomic 
classification of bacteria using some proteins as biomarkers or the comparison of the 
proteomics spectra of a group of related bacteria (Lay, 2000). MALDI-TOF MS has 
been successfully used for classification up to genus, species and subspecies level 
(Murray, 2010). The ability of this technique to differentiate between methicillin -
sensitive and methicillin-resistant Staphylococcus aureus projects its true potential in 
bacterial strain typing as well (Edwards-Jones et al., 2000). When MALDI-TOF MS 
was used to study the chemotaxonomic relations between MCy1366T with MCy10622 
and the other members of the family Myxococcaceae, the dendrogram obtained after 
data analysis showed clear delineation of the new isolates from Corallococcus 
Myxococcus and Pyxidicoccus spp.  
Based on the polyphasic analysis, especially 16S rRNA gene sequences, DNA-DNA 
hybridization and MALDI-TOF data, it could be determined that novel strains, 
MCy1366T and MCy10622 represent a new genus (Aggregicoccus) and species 
(Aggregicoccus edoensis).  
As exemplified in section 5.1, screening of novel taxa for secondary metabolites is a 
promising approach towards discovery of novel natural products. This suggests that 
screening of the novel isolates, MCy1366T and MCy10622 under optimum growth 
conditions and methodical analysis of its metabolome can lead to detection of yet 
unexplored products. 
E.3. Pyrronazols and phenazines from Nannocystis pusilla 
Bacteria of the genus Nannocystis represent the family Nannocystaceae within 
Myxococcales and are closely related to marine myxobacteria like Enhygromyxa, 
Pseudenhygromyxa and Plesiocystis. The secondary metabolite potential of 
Nannocystis spp. has not been thoroughly exploited. They have been reported to 
produce only few compounds like phenylnannolones (Ohlendorf et al., 2008), 
germacran (Reichenbach and Höfle, 2000), geosmin (Trowitzsch et al., 1981) and the 
siderophores called nannochelins (Kunze et al., 1992). This could be due to the 
description and availability of only two species in this genus, N. exedens and N. 
pusilla till date.  





Nannocystis pusilla, strain Ari7 was selected from the 50 myxobacterial strains which 
were screened when it showed some antifungal activity in the course of preliminary 
screening. During HPLC-UV-HRESIMS data analysis, it was found to produce 
pyrronazols, which had been identified previously in another Nannocystis strain but 
remained unpublished. Pyrronazols represent a novel structural class of secondary 
metabolites constituting chlorinated pyrrole-oxazole-pyrones showing very weak 
activity against the filamentous fungi, Mucor hiemalis. Three pyrronazol variants, 
pyrronazol A, A2 and B were isolated and characterized from strain Ari7. The other 
known derivatives of pyrronazol, pyrronazol C1 and pyrrronazol C2 had been isolated 
from N. pusilla, strain Na 174. Pyrronazols were detected in extracts from both 
species of Nannocystis, N. pusilla and N. exedens but not from any other 
myxobacteria screened during our screening program, which leads us to speculate 
that pyrronazols production is limited to this genus only and thus has the potential to 
be used as a chemotaxonomic biomarker in future.  
N. pusilla strains Ari7 and Na a174 were isolated from Langeoog Island in Germany 
and Rhodos Island in Greece, respectively, which suggests their close association 
with the marine environment. In this perspective, it is very fascinating to note the 
resemblance in the molecular structures of pyrronazols and phorbazoles, which have 
been isolated from the marine sponge, Phorbas aff. clathrata (Rudi et al., 1994) and 
the marine mollusk, Aldisa andersoni (Nuzzo et al., 2012). The detection of 
phorbazoles in A. andersoni extracts can be mostly accredited to their feeding on 
Phorbas sponges. Phorbazoles are chlorinated phenyl-pyrrolyl-oxazoles which differ 
in the number and position of the chlorine atoms.  
The two phorbazole derivatives, 9-chloro-phorbazole D and N1-methyl-phorbazole A 
exhibited good inhibitory activity against many human cancer cell lines (Nuzzo et al., 
2012) while pyrronazol A failed to show any significant activity against the cell lines 
tested. The similarity between the structures for both these classes of compounds 
suggests that chemical modification of pyrronazols might help to enhance their 
biological activity.  
Three other natural compounds closely related to pyrronazols are pyoluteorin 
(Takeda, 1958), pyrrolomycin B (Kaneda et al., 1981) and pyrrolnitrin (Arima et al., 





1964). Pyrrolnitrin and its derivatives were long known to be produced by 
Pseudomonas species but were discovered for the first time from a myxobacterial 
strain of Myxococcus fulvus (Gerth et al., 1982). Pyrrolnitrin was later detected in 
many other myxobacteria from the suborder Cystobacterineae including 
Corallococcus and Cystobacter (Gerth et al., 1982). 
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Fig.E2. Structures of pyrronazols and phorbazoles 
Natural products containing heterocyclic rings can also be found from other sources 
like fungi and plants besides bacteria and marine organisms (Gribble, 1996). The 
fungus Auxarthron umbrinum along with other members of order Onygenales are 
known to produce a pyrrolylpolyene called rumbrin (Yamagishi et al., 1993). Rumbrin 
structurally resembles pyrronazol with the presence of a pyrrole and a pyrone ring, 
here completely unsaturated. Rumbrin was found to possess potent cytoprotective 
(Yamagishi et al., 1993) and calcium-accumulation inhibitory activities (Yamagishi 
and Shindo, 1993). An isomer of rumbrin, 12E-isorumbrin also showed potent 
anticancer activity (Clark et al., 2006). It can be speculated that pyrronazols may also 





exhibit such distinct biological activities if tested in some exclusive screening 
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Fig. E3. Structure of Rumbrin 
N. pusilla, strain Ari7 also produced two phenazine compounds, 1,6-phenazinediol 
and 1-hydroxy-phenazine-6-yl-α-D-arabinofuranoside in addition to pyrronazols. 
Phenazines have been reported from a wide variety of bacteria like Nocardia, 
Brevibacterium, Burkholderia, Pseudomonas and Streptomyces (Dwivedi and Johri, 
2003,). The phenazine antibiotic, myxin was first isolated from Sorangium sp. and 
reported to exhibit potent antimicrobial activity (Peterson et al., 1966). 1,6-
phenazinediol was first reported from Streptomyces thioluteus (Akabori and 
Nakamura, 1959). 
Though phenazines are versatile natural compounds and more than 100 structural 
derivatives have been identified from numerous bacteria, phenazine glycosides are 
rarely encountered as natural products (Abdelfattah et al., 2011). Izuminosides 
(Abdelfattah et al., 2011), phenazoviridine (Kato et al., 1993), aestivopheonins (Shin-
Ya et al., 1995) and L-quinovose esters of saphenic acid (Pathirana et al., 1992) are 
amongst the few phenazine glycosides which have been primarily known to be 
produced by actinomycetes. This is the first report of the production of a phenazine 
glycoside from myxobacteria.  
Pseudomonads are known to suppress the growth and survival of competitive 
microbes by production of many secondary metabolites including pyrroles and 
phenazines (Dwivedi and Johri, 2003) and the occurrence of both these classes of 
compounds from a single myxobacterial strain suggest that the biosynthetic gene 





clusters or biosynthetic pathways for these two classes of compounds could be linked 
in some way. It also explains the antifungal effects of crude methanol extract of strain 
Ari7 and implicates the possibility of use of these compounds by the producer for its 
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With the advent of new pathogens and upsurge in the number of antibiotic resistant 
microbes, concerted efforts need to be made by pharmaceutical, biotechnological 
and academic communities to pace up the antibiotic discovery programs and combat 
these deadly pathogens to ensure progress in health sector. Natural products 
continue to be a plenteous source of new chemical entities with distinct biological 
activities in extended screening programs. Microbe derived natural products and 
analogues have found applications in wide range of fields from pharmaceuticals to 
agriculture.  
The present thesis mainly focused on natural products isolation and characterization 
from myxobacteria and Paenibacillus larvae and identification and description of a 
novel myxobacterial taxon, Aggregicoccus edoensis. In order to find new compounds, 
50 myxobacterial strains from our in house myxobacterial collection and two 
genotypes (ERIC I and ERIC II) of Paenibacillus larvae were cultivated and screened 
by biological assays, HPLC and HPLC-HRESIMS analysis. The compounds 
recognized as new metabolites were subsequently purified and characterized 
followed by structure elucidation.  
Pyrronazols and phenazine derivatives purified from Nannocystis pusilla, strain Ari7 
give an insight of yet unexhausted metabolic diversity of microbes, specifically, of 
myxobacteria. Furthermore, description of paenilarvins from P. larvae is the first 
report of purification of secondary metabolites from this deadly honey bee pathogen. 
It is known that novel microbial taxa have a huge potency to detect new secondary 
metabolites. Hence, with an aim to identify novel myxobacterial taxa amongst the 
group of myxobacteria screened for natural products, their 16S rRNA genes were 
analyzed and compared to representative strains of the validly published taxa to 
determine their position in the myxobacterial phylogeny. One strain which delineated 
from other myxobacterial strains during phylogenetic studies was compared to the 
type strains of closely related genera for proteomics, fatty acid content and antibiotic 
resistance and described as a representative of a new genus, Aggregicoccus 
edoensis. Comprehensive screening of this novel taxon can possibly grant access to 
new myxobacterial metabolites.   
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